<nodes>
	<node>
		<Fname>
contactus.html ./clinpharm/contactus.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/contactus.html</Path>
		<FileBody>
			&lt;meta HTTP&#45;EQUIV=&quot;REFRESH&quot; content=&quot;0; url=/people/admin.html&quot;&gt;
			&lt;/HEAD&gt;		</FileBody>
	</node>
	<node>
		<Fname>
Giving ./clinpharm/giving.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/giving.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;b&gt;The staff, fellows, and attending physicians in the Division of Clinical Pharmacology are committed to clinical research and basic science research.&lt;/b&gt;
			
			&lt;p&gt;In addition to conducting research, the Division of Clinical Pharmacology teaches medical students, pharmacy students, nursing students, residents, and fellows. We have an outstanding &lt;a href=&quot;/fellowship/&quot;&gt;Clinical Pharmacology and Therapeutics Postdoctoral Fellowship program&lt;/a&gt; that has trained and educated Clinical Pharmacologists for over 30 years.&lt;/p&gt;
			
			&lt;h3&gt;How You Can Help&lt;/h3&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;There are many ways to support the Division of Clinical Pharmacology at UCSF in its goals of patient care, research, and training. Donations from patients, family, and friends play a vital role in furthering our mission. If you are interested, please contact: &lt;br /&gt;
			&lt;blockquote&gt;&lt;b&gt;Lillian Samuel&lt;/b&gt;&lt;br /&gt;
			Senior Director of Development, Pharmacy &amp;amp; Graduate Programs&lt;br /&gt;
			Office Tel: (415) 502&#45;1197&lt;br /&gt;
			E&#45;mail: &lt;a href=&quot;mailto:lsamuel@support.ucsf.edu&quot;&gt;lsamuel@support.ucsf.edu&lt;/a&gt;&lt;/blockquote&gt;&lt;/p&gt;
			
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
google3632a1c783ccb7e7.html ./clinpharm/google3632a1c783ccb7e7.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/google3632a1c783ccb7e7.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Home ./clinpharm/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/index.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;p style=&quot;font&#45;family:serif;color:#003366;font&#45;size:16px;font&#45;style:italic;padding&#45;top:8px;&quot;&gt;Clinical pharmacology is recognized and serves as the premier discipline at the forefront of the discovery, development, regulation, and use (DDRU) of safe and effective medications necessary for the prevention and treatment of illness.&lt;/p&gt;
			
			&lt;p&gt;The Division of Clinical Pharmacology and Experimental Therapeutics at the University of California, San Francisco, has been engaged in these activities since 1965. The Department of Medicine (School of Medicine) and the Department of Bioengineering and Therapeutic Sciences (School of Pharmacy) jointly sponsor the Division. It maintains close ties with other clinical and basic research units of the University, including the Departments of Pharmacology, Pediatrics, Psychiatry, Epidemiology and the Cardiovascular Research Institute.&lt;/p&gt;
			
			
			&lt;div style=&quot;margin&#45;left:12px;margin&#45;right:12px;border:solid;border&#45;color:#99bbcc;border&#45;width:1px;padding:10px;border&#45;radius:15px&quot;&gt;
			
			&lt;b&gt;&lt;big&gt;Featured Article...&lt;/big&gt;&lt;/b&gt;&lt;br&gt;
			
			&lt;a href=&quot;http://cancer.ucsf.edu/research/cores/tobacco&#45;biomarkers&quot; target=&quot;_blank&quot;&gt;&lt;img src=&quot;images/tobacco.jpg&quot; class=&quot;imgRight&quot;&gt;&lt;/a&gt;&lt;p style=&quot;margin&#45;left:11px;&quot;&gt;&lt;h5&gt;About Tobacco Biomarkers Core&lt;/h5&gt;
			Many of the Division’s research projects involve measuring samples of tobacco biomarkers. &lt;br&gt;&amp;nbsp;&lt;br&gt;
			
			&lt;br&gt;&amp;nbsp;&lt;br&gt;
			&lt;a href=&quot;http://cancer.ucsf.edu/research/cores/tobacco&#45;biomarkers&quot; target=&quot;_blank&quot;&gt;&lt;i&gt;read more...&lt;/i&gt;&lt;/a&gt;&lt;/p&gt;
			
			&lt;/div&gt;
			
			&lt;br&gt;
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Home ./clinpharm/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/index.html~</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;p style=&quot;font&#45;family:serif;color:#003366;font&#45;size:16px;font&#45;style:italic;padding&#45;top:8px;&quot;&gt;Clinical pharmacology is recognized and serves as the premier discipline at the forefront of the discovery, development, regulation, and use (DDRU) of safe and effective medications necessary for the prevention and treatment of illness.&lt;/p&gt;
			
			&lt;p&gt;The Division of Clinical Pharmacology and Experimental Therapeutics at the University of California, San Francisco, has been engaged in these activities since 1965. The Department of Medicine (School of Medicine) and the Department of Bioengineering and Therapeutic Sciences (School of Pharmacy) jointly sponsor the Division. It maintains close ties with other clinical and basic research units of the University, including the Departments of Pharmacology, Pediatrics, Psychiatry, Epidemiology and the Cardiovascular Research Institute.&lt;/p&gt;
			
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;&lt;br&gt;
			
			&lt;table border=0 align=center cellpadding=0 cellspacing=0 bgcolor=#99bbcc style=&quot;margin&#45;left:13px;margin&#45;right:13px;&quot;&gt;
			&lt;tr&gt;
			&lt;td width=12&gt;
			&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/common/99bbcc&#45;topleft&#45;12.gif&quot;&gt;&lt;/td&gt;
			&lt;td&gt;&lt;/td&gt;
			&lt;td width=12&gt;
			&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/common/99bbcc&#45;topright&#45;12.gif&quot;&gt;&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;
			
			&lt;div style=&quot;margin&#45;left:12px;margin&#45;right:12px;&quot;&gt;
			
			&lt;b&gt;&lt;big&gt;Featured Article...&lt;/big&gt;&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:11px;&quot;&gt;Metformin is one of the most widely prescribed drug for the treatment of diabetes.  There is considerable individual variability in response to metformin.  The &lt;a href=&quot;/people/kgiacomini.html&quot;&gt;Giacomini&lt;/a&gt; research group has studied the influence of organic cation transporter 1 (OCT1), which is responsible for uptake of metformin by the liver, where it acts.  The Giacomini group, including &lt;a href=&quot;/people/fellows.html&quot;&gt;fellows&lt;/a&gt; in the UCSF clinical pharmacology training program, showed that deletion of the OCT1 gene in mice abolishes the glucose&#45;lowering effect of metformin in mice and that the effects of metformin in people who carry genes associated with reduced OCT1 function have a reduced response to metformin.  This research helps explain variability in response to metformin and may lead to ways to better individualize treatment for diabetics.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			
			
			&lt;a href=&quot;http://www.jci.org/articles/view/30558&quot; target=&quot;_blank&quot;&gt;&lt;i&gt;read more...&lt;/i&gt;&lt;/a&gt;&lt;/p&gt;
			
			&lt;/div&gt;
			
			&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td&gt;&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/common/99bbcc&#45;bottomleft&#45;12.gif&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/common/99bbcc&#45;bottomright&#45;12.gif&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
			&lt;/table&gt;&lt;br clear=all&gt;&lt;p&gt;
			
			&lt;br&gt;
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Home ./clinpharm/index_old.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/index_old.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;p style=&quot;font&#45;family:serif;color:#003366;font&#45;size:16px;font&#45;style:italic;padding&#45;top:8px;&quot;&gt;Clinical pharmacology is recognized and serves as the premier discipline at the forefront of the discovery, development, regulation, and use (DDRU) of safe and effective medications necessary for the prevention and treatment of illness.&lt;/p&gt;
			
			&lt;p&gt;The Division of Clinical Pharmacology and Experimental Therapeutics at the University of California, San Francisco, has been engaged in these activities since 1965. The Department of Medicine (School of Medicine) and the Department of Bioengineering and Therapeutic Sciences (School of Pharmacy) jointly sponsor the Division. It maintains close ties with other clinical and basic research units of the University, including the Departments of Pharmacology, Pediatrics, Psychiatry, Epidemiology and the Cardiovascular Research Institute.&lt;/p&gt;
			
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;&lt;br&gt;
			
			&lt;div style=&quot;margin&#45;left:12px;margin&#45;right:12px;border:solid;border&#45;color:#99bbcc;border&#45;width:1px;padding:10px;border&#45;radius:15px&quot;&gt;
			
			&lt;b&gt;&lt;big&gt;Featured Article...&lt;/big&gt;&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:11px;&quot;&gt;Metformin is one of the most widely prescribed drug for the treatment of diabetes.  There is considerable individual variability in response to metformin.  The &lt;a href=&quot;/people/kgiacomini.html&quot;&gt;Giacomini&lt;/a&gt; research group has studied the influence of organic cation transporter 1 (OCT1), which is responsible for uptake of metformin by the liver, where it acts.  The Giacomini group, including &lt;a href=&quot;/people/fellows.html&quot;&gt;fellows&lt;/a&gt; in the UCSF clinical pharmacology training program, showed that deletion of the OCT1 gene in mice abolishes the glucose&#45;lowering effect of metformin in mice and that the effects of metformin in people who carry genes associated with reduced OCT1 function have a reduced response to metformin.  This research helps explain variability in response to metformin and may lead to ways to better individualize treatment for diabetics.&lt;br&gt;&amp;nbsp;&lt;br&gt;
			
			
			&lt;a href=&quot;http://www.jci.org/articles/view/30558&quot; target=&quot;_blank&quot;&gt;&lt;i&gt;read more...&lt;/i&gt;&lt;/a&gt;&lt;/p&gt;
			
			&lt;/div&gt;
			
			&lt;br&gt;
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Clinical Pharmacology Lab ./clinpharm/lab.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/lab.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			The Clinical Pharmacology Laboratory at SFGH is under the leadership of &lt;a href=&quot;/people/nbenowitz.html&quot;&gt;Dr. Neal Benowitz, MD&lt;/a&gt;, an expert on smoking and health, and in particular the human pharmacology of nicotine. The division conducts research projects that focus on the study of human pharmacology of nicotine, with an emphasis on nicotine addiction. Among the issues currently being explored and studied include (1) the role of nicotine in controlling cigarette smoking and the use of other forms of tobacco; (2) the pathways and genetics of nicotine metabolism and pharmacological activity of nicotine breakdown substances; (3) phamacogenetics of nicotine addiction treatment; (4) racial/ethnic differences in nicotine pharmacology and addiction; (5) assessment of exposure to tobacco smoke in smokers and people exposed to secondhand smoke; (6) nicotine based tobacco regulation interventions; and (7) studies of exposure to smoke constituents from Hookah smoking and other novel smoking products.&lt;p&gt;
			
			Many of the Division's research projects involve measuring biofluid concentrations of drugs and metabolites, and biomarkers for toxic substance exposure.  The Clinical Pharmacology Laboratory (CPL), located at San Francisco General Hospital Medical Center, provides analytical chemistry support for research projects in the Division. In addition, CPL performs analyses to measure nicotine and/or its metabolites, caffeine and/or its metabolites, minor tobacco alkaloids, smoking cessation medications and selected carcinogen biomarkers for investigators outside our unit on a recharge or fee for service basis.&lt;p&gt;
			
			The CPL is directed by &lt;a href=&quot;/people/pjacob.html&quot;&gt;Dr. Peyton Jacob, III, PhD&lt;/a&gt;, and staffed with a team of 10 research personnel. The Laboratory is equipped with three triple&#45;quadrupole mass spectrometers (both GC and LC interfaces), a desktop GC&#45;MS system, HPLCs and GCs.  The CPL typically analyzes 10,000&#45;15,000 samples annually.&lt;p&gt;
			
			The Laboratory has been designated as a Core (Tobacco Biomarkers) for the UCSF Helen Diller Family Comprehensive Cancer Center. For more information about our Core facility, including a description of the analytical methods carried out at the CPL, their applications, and fee schedule, visit &lt;a href=&quot;http://cancer.ucsf.edu/tobacco&#45;biomarkers/&quot; target=&quot;_blank&quot;&gt;our website&lt;/a&gt;.&lt;p&gt;
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
News &amp; Events ./clinpharm/news.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/news.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Philanthropy ./clinpharm/philanthropy.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/philanthropy.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;b&gt;The staff, fellows, and attending physicians in the Division of Clinical Pharmacology are committed to clinical research and basic science research.&lt;/b&gt;
			
			&lt;p&gt;In addition to conducting research, the Division of Clinical Pharmacology teaches medical students, pharmacy students, nursing students, residents, and fellows. We have an outstanding &lt;a href=&quot;/fellowship/&quot;&gt;Clinical Pharmacology and Therapeutics Postdoctoral Fellowship program&lt;/a&gt; that has trained and educated Clinical Pharmacologists for over 30 years.&lt;/p&gt;
			
			&lt;b&gt;How you can help:&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;There are many ways to support the Division of Clinical Pharmacology at UCSF in its goals of patient care, research, and training. Donations from patients, family and friends play a vital role in furthering our mission. If you are interested, please contact Marc Olmsted at &lt;a href=&quot;mailto:molmsted@medsfgh.ucsf.edu&quot;&gt;molmsted@medsfgh.ucsf.edu&lt;/a&gt;; he can match your interest to the appropriate area.&lt;/p&gt;
			
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Resources ./clinpharm/resources.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/resources.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;b&gt;Related Research Sites&lt;/b&gt;
			
			&lt;ul&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://www.abcp.net/training.html&quot; target=&quot;_blank&quot;&gt;American Board of Clinical Pharmacology &#45; Training Programs&lt;/a&gt;&lt;p&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://www.accp.com/&quot; target=&quot;_blank&quot;&gt;American College of Clinical Pharmacy&lt;/a&gt; (ACCP)&lt;p&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://www.ascpt.org/&quot; target=&quot;_blank&quot;&gt;American Society for Clinical Pharmacology and Therapeutics&lt;/a&gt; (ASCPT)
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://www.ascpt.org/education/fellowship.cfm&quot; target=&quot;_blank&quot;&gt;Fellowship Opportunities&lt;/a&gt;
			&lt;/ul&gt;&lt;p&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://www.famri.org/core/&quot; target=&quot;_blank&quot;&gt;Flight Attendants Medical Research Institute&lt;/a&gt; (FAMRI)&lt;p&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://www.nigms.nih.gov/Initiatives/PGRN&quot; target=&quot;_blank&quot;&gt;Pharmacogenetics Research Network&lt;/a&gt; (PGRN)&lt;p&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://www.srnt.org/&quot; target=&quot;_blank&quot;&gt;Society for Research on Nicotine and Tobacco&lt;/a&gt; (SRNT)&lt;p&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;UCSF Research Sites&lt;/b&gt;
			
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://cancer.ucsf.edu/&quot; target=&quot;_blank&quot;&gt;Cancer Center&lt;/a&gt; (UCSF Helen Diller Family Comprehensive Cancer Center)&lt;p&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://tobacco.ucsf.edu/&quot; target=&quot;_blank&quot;&gt;Center for Tobacco Control Research and Education&lt;/a&gt; (CTCRE)&lt;p&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://bts.ucsf.edu/&quot; target=&quot;_blank&quot;&gt;Department of Bioengineering and Therapeutic Sciences&lt;/a&gt;&lt;p&gt;
			&lt;/ul&gt;
			&lt;br&gt;
			
			
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Patient Care ./clinpharm/care/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/care/index.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			&lt;br&gt;
			&lt;i&gt;coming soon&lt;/i&gt;
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Poison Center ./clinpharm/care/poisoncenter.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/care/poisoncenter.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			&lt;br&gt;
			&lt;i&gt;coming soon&lt;/i&gt;
			
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
index.html ./clinpharm/education/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/education/index.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Faculty Profiles ./clinpharm/faculty/faculty_profiles.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/faculty/faculty_profiles.html</Path>
		<FileBody>
			
		</FileBody>
	</node>
	<node>
		<Fname>
Faculty Profiles ./clinpharm/faculty/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/faculty/index.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;p class=&quot;bluify&quot;&gt;Our faculty have wide&#45;ranging research interests that cross the entire spectrum of clinical pharmacology and experimental therapeutics. Details of their academic and clinical interests can be found by clicking on each faculty member's name below.&lt;/p&gt;
			
			&lt;table border=0 cellspacing=6px style=&quot;margin:12px;&quot;&gt;
			&lt;tr valign=top&gt;&lt;td width=50%&gt;&lt;b&gt;Cardiovascular Pharmacology&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=028485183&quot;&gt;Mary O. Gray, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=024338485&quot;&gt;Joel S. Karliner, MD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Drug Development &amp;amp; Regulatory Science&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;Howard K. Lee, MD, PhD
			&lt;li&gt;Carl C. Peck, MD
			&lt;li&gt;Daniel A. Spyker, MD, PhD
			&lt;/ul&gt;
			
			&lt;b&gt;Geriatric Clinical Pharmacology&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=027444298&quot;&gt;Janice B. Schwartz, MD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Health Policy Studies&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=020637666&quot;&gt;Lisa Bero, PhD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Infectious Diseases &amp;amp; Antimicrobial Research&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=021370259&quot;&gt;Henry F. Chambers, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=023229305&quot;&gt;B. Joseph Guglielmo, PharmD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Investigational Therapeutics&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=025665209&quot;&gt;Pamela N. Munster, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=027733682&quot;&gt;Eric Small, MD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Medical Toxicology&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;Christine Haller, MD
			&lt;li&gt;Kent R. Olson, MD
			&lt;/ul&gt;
			
			&lt;/td&gt;&lt;td width=50%&gt;
			&lt;b&gt;Neuropsychopharmacology &amp;amp; Analgesiology&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=020097820&quot;&gt;Brian K. Alldredge, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=024263501&quot;&gt;Reese T. Jones, MD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Pediatric Clinical Pharmacology&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=022420061&quot;&gt;Michael Cabana, MD, MPH&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=023677404&quot;&gt;Melvin B. Heyman, MD, MPH&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=024625881&quot;&gt;Ronald M. Krauss, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=027089119&quot;&gt;Jennifer M. Puck, MD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Personalized Medicine&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=026576926&quot;&gt;Kathryn A. Phillips, PhD, MPA&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Pharmacogenetics, Molecular Pharmacology, Pharmacodynamics &amp;amp; Drug Disposition&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=024276586&quot;&gt;Nadav Ahituv, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=020293502&quot;&gt;Francesca T. Aweeka, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=020577409&quot;&gt;Leslie Z. Benet, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=020596474&quot;&gt;Neal L. Benowitz, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=026185116&quot;&gt;Esteban Gonz&amp;aacute;lez Burchard, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=021606322&quot;&gt;Bruce Conklin, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=021678495&quot;&gt;Maria Almira Correia, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=021981261&quot;&gt;Delia A. Dempsey, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=022598965&quot;&gt;Leslie Carstensen Floren, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=022908842&quot;&gt;Kathleen M. Giacomini, PhD&lt;/a&gt;
			&lt;li&gt;Peyton Jacob III, PhD
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=024639031&quot;&gt;Deanna L. Kroetz, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=029283876&quot;&gt;Elad Ziv, MD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Pharmacometrics&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=027278001&quot;&gt;Nancy C. Sambol, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;https://pharmacy.ucsf.edu/rada&#45;savic&quot; target=&quot;_blank&quot;&gt;Rada Savic, PhD&lt;/a&gt;
			&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;http://clinpharm&#45;sandbox.ucsf.edu/faculty/faculty_profiles.html?key=028584720&quot;&gt;Davide Verotta, PhD&lt;/a&gt;
			&lt;/ul&gt;
			&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Staff ./clinpharm/fellowship/admin.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/fellowship/admin.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;p&gt;&amp;nbsp;&lt;/p&gt;
			&lt;table align=center border=&quot;0&quot; cellpadding=2&gt;
			&lt;TR vAlign=top&gt; 
			&lt;th&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/th&gt;
			&lt;th&gt;&lt;b&gt;Physical Address&lt;/b&gt;&lt;/th&gt;
			&lt;th&gt;&lt;b&gt;Mailing Address&lt;/b&gt;&lt;/th&gt;
			&lt;/TR&gt;
			&lt;TR vAlign=top bgcolor=#eeeeee&gt;
			  &lt;TD&gt;&lt;b&gt;UCSF Division of Clinical Pharmacology &amp;amp; Experimental Therapeutics&lt;/b&gt;&lt;/td&gt;
			  &lt;td bgcolor=#eeeeee&gt;1550 &#45; 4th St., Mission Bay 584&lt;BR&gt;
			University of California, San Francisco&lt;BR&gt;
			San Francisco, CA. 94143 &#45; 2911&lt;br&gt;
			Fax: (415) 514&#45;4365&lt;/td&gt;
			  &lt;td bgcolor=#eeeeee&gt;UCSF Division of Clinical Pharmacology &amp;amp; Experimental Therapeutics&lt;br&gt;
			San Francisco, CA 94143&#45;2911&lt;/TD&gt;
			&lt;/TR&gt;
			
			&lt;TR vAlign=top&gt; 
			&lt;td class=&quot;other&quot;&gt;
			&lt;B&gt;Esteban Gonz&amp;aacute;lez Burchard, MD&lt;/B&gt;&lt;br&gt;
			Assistant Professor, Bioengineering &amp;amp; Therapeutic Sciences and Medicine&lt;br&gt;
			Director, Clinical Pharmacology Fellowship Program&lt;/td&gt;
			&lt;TD class=&quot;other&quot;&gt;Rock Hall, Mission Bay&lt;br&gt;
			1550 4&lt;sup&gt;th&lt;/sup&gt; Street, RH&#45;584C&lt;br&gt;
			San Francisco, CA 94158&lt;br&gt;
			(415) 514&#45;9677
			&lt;/TD&gt;
			&lt;TD class=&quot;other&quot;&gt;UCSF Department of Bioengineering &amp;amp; Therapeutic Sciences&lt;br&gt;
			San Francisco, CA 94143&#45;2911&lt;br&gt;
			&lt;a href=&quot;mailto:esteban@sfgh.ucsf.edu&quot;&gt;esteban@sfgh.ucsf.edu&lt;/a&gt;
			&lt;/td&gt;
			&lt;/TR&gt;
			
			&lt;TR vAlign=top&gt; 
			&lt;TD bgcolor=eeeeee&gt;
			&lt;B&gt;Leslie Carstensen Floren, PharmD&lt;/B&gt;&lt;br&gt;
			Assistant Adjunct Professor of Bioengineering &amp;amp; Therapeutic Sciences&lt;br&gt;
			Co&#45;Director, Clinical Pharmacology Fellowship Program&lt;/td&gt;
			&lt;TD bgcolor=#eeeeee&gt;Byers Hall, Mission Bay&lt;br&gt;
			1700 4&lt;sup&gt;th&lt;/sup&gt; Street, BH&#45;216D&lt;br&gt;
			San Francisco, CA 94158&lt;br&gt;
			(415) 514&#45;3559
			&lt;/TD&gt;
			&lt;td bgcolor=#eeeeee&gt;UCSF Department of Bioengineering &amp;amp; Therapeutic Sciences&lt;br&gt;
			San Francisco, CA 94143&#45;2911&lt;br&gt;
			&lt;a href=&quot;mailto:leslie.floren@ucsf.edu&quot;&gt;leslie.floren@ucsf.edu&lt;/a&gt;
			&lt;/td&gt;
			&lt;/TR&gt;
			
			&lt;TR vAlign=top&gt; 
			&lt;td class=&quot;other&quot;&gt;&lt;b&gt;Christine Mok &lt;/b&gt;&lt;br&gt;
			Administrative Analyst&lt;/td&gt;
			&lt;td class=&quot;other&quot;&gt;1550 &#45; 4th St., Mission Bay 584&lt;BR&gt;
			University of California, San Francisco&lt;BR&gt;
			San Francisco, CA. 94143 &#45; 2911&lt;br&gt;
			(415) 514&#45;4273&lt;/td&gt;
			&lt;td  class=&quot;other&quot;&gt;UCSF Division of Clinical Pharmacology &amp;amp; Experimental Therapeutics&lt;br&gt;
			San Francisco, CA 94143&#45;2911&lt;br&gt;
			&lt;a href=&quot;mailto:ptarr@medsfgh.ucsf.edu&quot;&gt;christine.mok@ucsf.edu&lt;/a&gt;&lt;/TD&gt;
			&lt;/TR&gt;
			
			&lt;/table&gt;
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Clinical Training ./clinpharm/fellowship/clinical_training.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/fellowship/clinical_training.html</Path>
		<FileBody>
						
			
			
			
			&lt;p&gt;Our goal is to train health care and biopharmaceutical research scientists (M.D.s, Pharm.D.s and Ph.D.s) who have knowledge and expertise in drug action, in the rational and cost&#45;effective use of drugs and the diagnosis and management of adverse effects of drug use.  Our trainees are expected to develop research skills in some area of clinical pharmacology, with the intent both to acquire new knowledge and to have the experience required to evaluate and interpret pharmacologic research, which is necessary to make decisions about rational therapeutics.  Many, but not all, trainees will become full time clinical research scientists in academic settings.  Other trainees are likely to become involved in drug development in the pharmaceutical industry and others in drug regulation.  Finally, we are training fellows to be teachers &#45; of therapeutic principles, rational use of drugs for specific medical diseases, and evaluation and management of toxicologic problems.   Most of our trainees will spend their careers associated with schools of medicine or pharmacy, where teaching and scholarly research are an essential activities.  Specifically, we would like our fellows to become skilled in most or all the following activities.&lt;/p&gt;
			
			
			
			&lt;p&gt;&lt;b&gt;Health Care Service Activities&lt;/b&gt;&lt;/p&gt;
			
			&lt;ol type=A&gt;
			&lt;li&gt;&lt;u&gt;Direct Patient Services&lt;/u&gt;
			&lt;ol&gt;
			&lt;li&gt;Consultation on therapeutic problems, adverse drug reactions or lack of therapeutic response.  This requires knowledge of pharmacologic action of drugs, principles of pharmacokinetics and pharmacodynamics, and knowledge of the influence of disease states on drug action. 
			&lt;li&gt;Evaluation and management of acute poisoning and other toxicologic emergencies and active involvement in poison control centers. 
			&lt;li&gt;Therapeutic drug monitoring.
			&lt;/ol&gt;
			&lt;li&gt;&lt;u&gt;Indirect Patient Services&lt;/u&gt;
			&lt;ol&gt;
			&lt;li&gt;Hospital monitoring of drug use and effects, including adverse drug reaction monitoring.
			&lt;li&gt;Participation in Pharmacy and Therapeutics Committees.
			&lt;li&gt;Involvement in cost&#45;effective management of medication use.
			&lt;li&gt;Advice to colleagues concerning design and conduct of clinical research.
			&lt;/ol&gt;
			&lt;li&gt;&lt;u&gt;Society&lt;/u&gt;
			&lt;ol&gt;
			&lt;li&gt;Participation in continuing medical education of physicians, continuing education of pharmacists and education of lay audiences about pharmacologic health issues.
			&lt;li&gt;Knowledge about and participation in adverse drug reactions surveillance.
			&lt;li&gt;Participation in governmental advisory committees related to therapeutic policies.
			&lt;/ol&gt;&lt;/ol&gt;
			
			&lt;p&gt;&lt;b&gt;Teaching&lt;/b&gt;&lt;/p&gt;
			
			&lt;p&gt;Fellows are expected to develop a knowledge base and skills in teaching at several levels: (a) teaching of medical and pharmacy students, both pre&#45;clinical and clinical; (b) teaching of housestaff, primarily bedside teaching; and (c) postgraduate teaching, including participation in continuing medical and pharmacy education courses.&lt;/p&gt;
			
			&lt;p&gt;
			&lt;strong&gt;Intern Licences&lt;/strong&gt;
			&lt;/p&gt;
			&lt;p&gt;
			&lt;u&gt;QUALIFYING METHOD&lt;/u&gt;&lt;br&gt;
			&lt;strong&gt;A&lt;/strong&gt;
			&lt;/p&gt;
			
			
			&lt;p&gt;
			To apply for registration as an intern pharmacist in California, you must be:
			
			&lt;ul&gt;
			&lt;li&gt;Currently enrolled in a school of pharmacy recognized by the board or accredited by the
			Accreditation Council for Pharmaceutical Education (ACPE),
			&lt;/ul&gt;
			&lt;/p&gt;&lt;p&gt;
			&lt;strong&gt;OR&lt;/strong&gt;
			&lt;/p&gt;&lt;p&gt;
			&lt;ul&gt;
			&lt;li&gt;A graduate of a school of pharmacy recognized by the board or accredited by the
			Accreditation Council for Pharmaceutical Education (ACPE) who also has an application
			pending to become licensed as a pharmacist in California,
			&lt;/ul&gt;
			&lt;/p&gt;&lt;p&gt;
			&lt;strong&gt;OR&lt;/strong&gt;
			&lt;/p&gt;&lt;p&gt;
			&lt;ul&gt;
			&lt;li&gt;
			A graduate of a foreign pharmacy school who has obtained certification from the Foreign
			Pharmacy Graduate Examination Committee (FPGEC). 
			&lt;/ul&gt;
			&lt;/p&gt;
			&lt;strong&gt;
			&lt;p&gt;
			NOTE: You will not be issued an intern registration until the board has received written verification from the FPGEC that you have obtained this certification. 
			&lt;/p&gt;
			&lt;p&gt;
			(This process will take up to 12 weeks for the FPGECto provide your results to the board.)
			&lt;/p&gt;
			&lt;/strong&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Didactic Courses &amp; Seminars ./clinpharm/fellowship/didactic.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/fellowship/didactic.html</Path>
		<FileBody>
						
			&lt;p&gt;&lt;b&gt;Didactic Courses&lt;/b&gt;&lt;/p&gt;
			
			&lt;p&gt;In addition to the NIH sponsored didactic course, &lt;i&gt;Principles of Clinical Pharmacology&lt;/i&gt;, trainees are encouraged to take other courses to develop specific expertise in biomathematics, computer science, pharmacokinetics, statistics, clinical trial design or other research&#45;related skills, which are relevant to their particular research emphasis.  These courses are offered by the School of Pharmacy, the Department of Medicine, the Cardiovascular Research Institute, and the Department of Epidemiology and Biostatistics.&lt;/p&gt;
			
			&lt;ol&gt;
			&lt;li&gt;&lt;b&gt;School of Pharmacy Courses&lt;/b&gt;&lt;p&gt;
			
			&lt;ul&gt;
			&lt;li&gt;Basic Principles of Pharmaceutical Sciences PSPG 245A (this course focuses on fundamental mechanisms of membrane transport, pharmacokinetics, modeling, and quantitation)&lt;p&gt;
			
			&lt;li&gt;Basic Principles of Pharmaceutical Sciences PSPG 245B (this course focuses on mechanisms of pharmacology, toxicology, and drug metabolism barriers to drug delivery)&lt;p&gt;
			
			&lt;li&gt;Basic Principles of Pharmaceutical Sciences PSPG 245C (an introduction into the genetic factors underlying the efficacy and toxicity of drugs. Topics to be covered include genomic methods in drug design, drug development and drug therapy)&lt;p&gt;
			
			&lt;li&gt;PSPG 271:  Advanced Pharmacokinetics in Clinical Drug Development  (significant time will be devoted to theoretical aspects of the various topics, the focus will be on practical examples (real data) in how to design and interpret pharmacokinetic studies for use as a component of the regulatory drug approval process)&lt;p&gt;
			
			&lt;/ul&gt;
			&lt;li&gt;&lt;b&gt;Department of Medicine &amp; Cardiovascular Research Institute (CVRI) Courses&lt;/b&gt;&lt;p&gt;
			
			&lt;ul&gt;
			&lt;li&gt;Statistics&lt;p&gt;
			
			&lt;li&gt;Scientific Writing&lt;p&gt;
			
			&lt;li&gt;Physiology 302 &#45; The Art of Lecturing and Small Group Teaching&lt;p&gt;
			
			&lt;/ul&gt;
			&lt;li&gt;&lt;b&gt;Department of Epidemiology and Biostatistics Courses&lt;/b&gt;&lt;p&gt;
			
			&lt;ul&gt;
			&lt;li&gt;&lt;i&gt;Training in Clinical Research&lt;/i&gt; (TICR) program: &lt;a href=&quot;http://www.epibiostat.ucsf.edu/courses/summerworkshop.html&quot; target=&quot;_blank&quot;&gt;Summer Clinical Research Workshop&lt;/a&gt;&lt;br&gt;
			Fellows will participate in a seven week program consisting of three courses (&lt;a href=&quot;http://www.epibiostat.ucsf.edu/courses/schedule/clin_research.html&quot; target=&quot;_blank&quot;&gt;Designing Clinical Research&lt;/a&gt;, &lt;a href=&quot;http://www.epibiostat.ucsf.edu/courses/schedule/responsible_conduct.html&quot; target=&quot;_blank&quot;&gt;Responsible Conduct of Research&lt;/a&gt;, and &lt;a href=&quot;http://www.epibiostat.ucsf.edu/courses/schedule/building_academic_career.html&quot; target=&quot;_blank&quot;&gt;Building a Career in Clinical Research&lt;/a&gt;) that provides instruction in the development of clinical research proposals that are scientifically sound, ethically appropriate, and provide entry to a career in academic medicine.&lt;p&gt;
			
			&lt;li&gt;&lt;a href=&quot;http://www.epibiostat.ucsf.edu/courses/ATCR.html&quot; target=&quot;_blank&quot;&gt;Advanced Training in Clinical Research&lt;/a&gt; (ATCR)&lt;br&gt;
			A year long sequel to TICR Summer Program which provided further training to enable fellows to:
			&lt;ul&gt;
			&lt;li&gt;Plan, acquire funding for, and conduct clinical research
			&lt;li&gt;Analyze the data and interpret the results of their research
			&lt;li&gt;Present their research at scientific meetings and in the medical literature
			&lt;li&gt;Critique and interpret the research of others
			&lt;/ul&gt;&lt;p&gt;
			&lt;/ol&gt;
			
			&lt;p&gt;&lt;b&gt;Seminars&lt;/b&gt;&lt;/p&gt;
			
			&lt;ol&gt;
			&lt;li&gt;&lt;b&gt;Clinical Pharmacology Didactic Seminar&lt;/b&gt;&lt;br&gt;
			All first year fellows will participate in an intensive PK/PD workshop series (based upon the UCSF&#45;sponsored course &lt;i&gt;Pharmacokinetics for Pharmaceutical Scientists&lt;/i&gt;) from  July &#45; August consisting of weekly sessions to review PK and PD problem sets.  The topics that are covered include: a general introduction to pharmacokinetics with an emphasis on clinical applications; clearance concepts; drug distribution concepts and IV bolus kinetics; constant rate input; absorption concepts and kinetics; renal and hepatic (metabolic) drug elimination.&lt;p&gt;
			
			Additionally, one day per week from the beginning of September through the end of April, the didactic seminar follows the &lt;i&gt;Principles of Clinical Pharmacology&lt;/i&gt; course outline, which is sponsored by the NIH Clinical Center.  This weekly lecture series, consisting of 31 lectures in total, covers the fundamentals of clinical pharmacology as a translational scientific discipline focused on rational drug development and utilization in therapeutics and is divided into five broadly categorized &quot;Training Modules&quot; including: Pharmacokinetics, Drug Metabolism and Transport, Assessment of Drug Effects, Optimizing and Evaluating Patient Therapy, and Drug Discovery and Development.  This lecture series will be given every other year.&lt;p&gt;
			
			In addition, during the period from Fall through Spring, we hold a bi&#45;monthly journal club in addition to the weekly lectures.  The journal articles are selected to correspond with the topic discussed in the &lt;i&gt;Principles of Clinical Pharmacology&lt;/i&gt; lecture for that week.&lt;p&gt;
			
			&lt;li&gt;&lt;b&gt;Journal Clubs&lt;/b&gt;&lt;br&gt;
			Fellows participate in a bi&#45;monthly journal club during which time the fellows present salient articles and are joined by a faculty discussant who has  particular expertise in the research area covered in the journal articles. 
			The journal club activity serves two main purposes.  First, it provides a forum for group discussion of issues of common interest to all fellows.  Fellows select one or two papers on a particular topic and a particular faculty person is invited to comment.  Topics might include issues of drug development, clinical trial design or analysis, evaluating adverse drug reactions, urine drug screening, etc.  Sessions are included on the ethics of biomedical research and human experimentation.&lt;p&gt;
			
			The second purpose is to teach fellows how to critique and judge the validity of drug&#45;related research.  On alternate years the fellows review a self&#45;study course, &lt;i&gt;Studying a Study, Testing a Test&lt;/i&gt;.  In this course the types of experimental design for various types of medical research and potential pitfalls, along with examples from well&#45;known research studies are discussed.&lt;p&gt;
			
			The journal clubs are attended by one or more faculty members who have particular interest and/or experience in the topic.  Some of our faculty (in addition to Drs. Burchard and Benowitz) who do considerable fellows journal club teaching are Drs. Floren (clinical pharmacology and other topics in general clinical pharmacology), Dempsey (adverse drug reactions, pediatric clinical pharmacology), Haller (drug safety, alternative medications), Schwartz (cardiovascular and geriatric clinical pharmacology), Giacomini and Kroetz (drug metabolism and transport) and Spyker (drug development).&lt;p&gt;
			
			&lt;li&gt;&lt;b&gt;Clinical Pharmacology Research Seminar&lt;/b&gt;&lt;br&gt;
			Fellows and faculty present their research at this seminar, which occurs every trimester.  These seminars are intended to address research design, progress, problems encountered, and interpretation of results and plans for future research rather than accounts of finished work.  The presentations are closely scrutinized and critiqued by other faculty and fellows.  Through this seminar, research endeavors of fellows and faculty are critiqued at a time when input into the research can be most useful.  This seminar teaches fellows how to design research and to critically review research data, gives the fellows exposure to various areas of pharmacologic research and methods used in such research, and gives them experience in presenting organized research seminars.&lt;p&gt;
			
			&lt;/ol&gt;
			
			&lt;p&gt;&lt;b&gt;Optional Conferences&lt;/b&gt;&lt;p&gt;
			
			&lt;p&gt;Of the large number of regular conferences and seminars presented at UCSF, these will be of particular interest to fellows:&lt;/p&gt;
			
			&lt;ol type=a style=&quot;margin&#45;left:33px;&quot;&gt;
			&lt;li&gt;UCSF Medical Grand Rounds 8:00&#45;9:00am Thursdays Toland Hall
			&lt;li&gt;SFGH Medical Grand Rounds: 12:00&#45;1:00pm Tuesdays Carr Auditorium
			&lt;/ol&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Fellows ./clinpharm/fellowship/fellows.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/fellowship/fellows.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/fellowgrad.jpg&quot; alt=&quot;2017 Graduation Celebration&quot; caption=&quot;2017 Graduation Celebration&quot;&gt;
			&lt;p class=&quot;caption&quot; style=&quot;width:393px;&quot;&gt;&lt;b&gt;2017 Graduation Celebration&lt;/b&gt;&lt;/p&gt;
			&lt;/br&gt;
			
			&lt;h4&gt;CURRENT FELLOWS:&lt;/h4&gt;
			
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/oni&#45;orisan.png&quot;&gt;&lt;b&gt;Akinyemi &quot;Akin&quot; Oni&#45;Orisan, PharmD, PhD, DABCP&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;&lt;i&gt;Project Description:&lt;/i&gt; The goal of this project is to identify genetic determinants of response to statin therapy. We are utilizing electronic health records which are linked to genetic information to integrate molecular, clinical and environmental data. &lt;/p&gt;&lt;br /&gt;&lt;br /&gt;
			
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;
			&lt;br /&gt;
			
			
			
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/bartelink.jpg&quot;&gt;&lt;b&gt;Imke Bartelink, PhD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;&lt;i&gt;Research Topic:&lt;/i&gt; Associate of drug concentrations at the pharmacological target site with toxicity and efficacy, in order to individualize drug treatment with an optimal risk&#45;benefit ratio in early phase oncology trials. &lt;/p&gt;&lt;br /&gt;&lt;br /&gt;
			
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;
			&lt;br /&gt;
			
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/mcgarry_meghan.jpg&quot;&gt;&lt;b&gt;Meghan McGarry, MD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Meghan McGarry is a Pediatrician who is currently a Clinical Fellow in the Pediatric Pulmonary department at University of California, San Francisco.  She is working with Dr. Esteban Burchard studying the relationship of genetics and drug response in children with asthma from minority populations.  She is also working with Dr. Dennis Nielson on a clinical trial studying the effects of new pharmacotherapy in patients with cystic fibrosis.  &lt;/p&gt;&lt;br /&gt;&lt;br /&gt;
			
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;
			&lt;br /&gt;
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/wattier_rachel.jpg&quot;&gt;&lt;b&gt;Rachel Wattier, MD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Rachel Wattier is a pediatrician who is interested in appropriate use of antimicrobial agents in the management of immunocompromised hosts. She is working with Dr. Peggy Weintrub and Dr. Christopher Dvorak on a project addressing management of fever in children undergoing treatment for cancer. She is concurrently completing a fellowship in Pediatric Infectious Diseases.&lt;/p&gt;&lt;br /&gt;&lt;br /&gt;
			
			
			
			&lt;h4&gt;PAST FELLOWS:&lt;/h4&gt;
			&lt;br /&gt;
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/hibma_jen.jpg&quot;&gt;&lt;b&gt;Jen Hibma, PharmD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Jennifer Hibma is trained as a clinical pharmacist and recently completed her Pharm.D. at the University of California, San Francisco.  She is currently working in the laboratory of Dr. Kathy Giacomini on clinical pharmacogenomics of membrane transporters.&lt;/p&gt;&lt;br /&gt;&lt;br /&gt;
			
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;
			&lt;br /&gt;
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/thakur_neeta.jpg&quot;&gt;&lt;b&gt;Neeta Thakur, MD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Neeta is a physician specializing in pulmonary diseases who is interested in studying social and environmental determinants of asthma. Her research focus is understanding how individuals internalize chronic stress and how social and environmental stress modify the course of asthma. Neeta received her MD and Masters in Public Health from the University of Arizona and completed her Internal Medicine residency at UCSF, where she is currently a Pulmonary and Critical Care Medicine fellow.&lt;/p&gt;&lt;br /&gt;
			
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;
			&lt;br /&gt;
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/giacomini_marilyn.jpg&quot;&gt;&lt;b&gt;Marilyn Giacomini, PhD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Marilyn Giacomini received her Ph.D. in Pharmaceutical Sciences and Pharmacogenomics at UCSF in 2011.  Currently, she is a post&#45;doctoral fellow in Deanna Kroetz’s lab at UCSF where she is investigating the impact of genetic polymorphisms in modulating drug&#45;drug interactions.  Specifically, she is studying the effect of a common genetic polymorphism in SLCO1B1 on an important drug&#45;drug interaction between the immunosuppressant, cyclosporin A and pravastatin. &lt;/p&gt;&lt;br /&gt;
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;
			&lt;br /&gt;
			&lt;br /&gt;
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/Doernberg2.jpg&quot;&gt;&lt;b&gt;Sarah Doernberg, MD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Sarah Doernberg is trained in Internal Medicine and is currently an Infectious Diseases fellow at UCSF. She worked with Drs &lt;a href=&quot;http://id.medicine.ucsf.edu/about/facpages/chambers.html&quot; target=&quot;_blank&quot;&gt;Chip Chambers&lt;/a&gt;, &lt;a href=&quot;http://www.faculty.uci.edu/profile.cfm?faculty_id=5274&quot; target=&quot;_blank&quot;&gt;Catherine Liu&lt;/a&gt;, and &lt;a href=&quot;http://id.medicine.ucsf.edu/about/facpages/winston.html&quot; target=&quot;_blank&quot;&gt;Lisa Winston&lt;/a&gt; with a focus on hospital epidemiology and infection control. &lt;/p&gt;&lt;br clear=all&gt;&lt;br&gt;
			
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;
			
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/afrymoyer101.jpg&quot;&gt;&lt;b&gt;Adam Frymoyer, MD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Adam Frymoyer is a pediatrician and worked with &lt;a href=&quot;lbenet.html&quot;&gt;Dr. Leslie Benet&lt;/a&gt;. He studied drug transporters and participated in clinical studies of antibiotics in children.&lt;/p&gt;
			&lt;br clear=all&gt;&lt;br&gt;
			
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;&lt;br&gt;
			
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/jgalanter101.jpg&quot;&gt;&lt;b&gt;Joshua Galanter, MD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Joshua Galanter is an internist with training in pulmonary and critical care medicine.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;He worked with &lt;a href=&quot;eburchard.html&quot;&gt;Dr. Esteban Burchard&lt;/a&gt;.  The focus of his research is the interplay between genetics, the environment and drug response, especially among children from minority populations.&lt;/p&gt;&lt;br clear=all&gt;&lt;br&gt;
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;&lt;br&gt;
			&lt;br&gt;
			&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/chaass&#45;koffler101.jpg&quot; class=&quot;imgRight&quot;&gt;&lt;b&gt;Carolina Haass&#45;Koffler, PharmD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Carolina Haass&#45;Koffler completed her doctoral degree in Pharmacy in the Pharmaceutical Science Pathway and she worked with Drs &lt;a href=&quot;http://www.galloresearch.org/index.php/translationalresearch/preclinical/preclinicalmembers/23&#45;preclinicalmembers/83&#45;preclinicalselenab&quot; target=&quot;_blank&quot;&gt;Selena Bartlett&lt;/a&gt; and &lt;a href=&quot;http://www.galloresearch.org/index.php/investigators/abonci&quot; target=&quot;_blank&quot;&gt;Antonello Bonci&lt;/a&gt; in the Medication Development/Transitional Research group at the Ernest Gallo Clinic &amp;amp; Research Center.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Haass&#45;Koffler's research interest was determining the physiological role of Corticotropin&#45;releasing&#45;factor binding&#45;protein (CRF&#45;BP), its interaction with its ligand (CRF) and receptors GPCRs. CRF&#45;BP was originally thought to have simply a buffer role, preventing excessive levels of CRF during stressful events. However, we postulated that CRF&#45;BP is not just a sink for CRF, but has an active role in the CRF&#45;mediate processes and the potentiation of NMDA receptor signaling. Dr. Haass&#45;Koffler is also interested in the effect of CRF&#45;BP on psychiatric disorders and its role in reinstatement of cocaine and alcohol seeking behaviors.&lt;/p&gt;
			
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;&lt;br&gt;
			
			
			
			
			
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/wlorizio101.jpg&quot;&gt;&lt;b&gt;Wendy Lorizio, MD, MPH&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Wendy Lorizio is trained in medicine and epidemiology and she worked with Drs &lt;a href=&quot;eziv.html&quot;&gt;Elad Ziv&lt;/a&gt; and &lt;a href=&quot;eburchard.html&quot;&gt;Esteban Burchard&lt;/a&gt;.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Lorizio's research interests are cancer, genetic epidemiology and pharmacogenetics, with a particular focus on minority populations, especially Latinas. Her specific research project was study the interaction among genetic polymorphisms of the estrogen receptor alpha and beta genes, the &lt;i&gt;CYP2D6&lt;/i&gt; gene and serum biomarkers such as IGF&#45;1 and osteocalcin as predictors of adverse effects from tamoxifen in women being treated for breast cancer. Dr Lorizio also studied the decision process of women deciding whether to take tamoxifen and how &lt;i&gt;CYP2D6&lt;/i&gt; genotyping affects that decision.&lt;/p&gt;&lt;br clear=all&gt;&lt;br&gt;
			
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;&lt;br&gt;
			
			
			
			
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/Kussmaul2.jpg&quot;&gt;&lt;b&gt;Susannah Kussmaul, MD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Susannah Kussmaul is a pediatrician who is interested in pharmacoepidemiology, specifically the judicious use of antibiotic therapy. She worked with Drs &lt;a href=&quot;http://clinicalpharmacy.ucsf.edu/faculty/bio.asp?bioid=%7BB1F14486&#45;3CB8&#45;48F8&#45;BEE0&#45;F4DFE718C5D1%7D&quot; target=&quot;_blank&quot;&gt;B. Joseph Guglielmo&lt;/a&gt; and &lt;a href=&quot;http://www.ucsfbenioffchildrens.org/cgi&#45;bin/expertDetail.cgi?doctorid=1287&quot; target=&quot;_blank&quot;&gt;Jay Tureen&lt;/a&gt; on a research project focusing on novel methods for treating intravascular&#45;related infections in children. She concurrently completed a fellowship in Pediatric Infectious Diseases.&lt;/p&gt;&lt;br clear=all&gt;&lt;br&gt;
			&lt;br&gt;
			&lt;HR align=center width=&quot;60%&quot; color=#b33700 SIZE=1&gt;
			                  &lt;BR&gt;
			                  &lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/Munji.jpg&quot;&gt;&lt;b&gt;Roeben Munji, MD&lt;/b&gt;&lt;br&gt;
			                  &lt;P style=&quot;MARGIN&#45;LEFT: 12px&quot;&gt;Dr. Roeben Munji conducted his doctoral research in the field of neuroscience. He worked  with Drs &lt;a href=&quot;http://profiles.ucsf.edu/ProfileDetails.aspx?Person=5506330&quot; target=&quot;_blank&quot;&gt;Roland Bainton&lt;/a&gt; and Richard Daneman on a research project focusing on identifying new genes and genetic pathways that regulate blood&#45;brain barrier (BBB) function. The BBB is a cellular and molecular barrier that protects the brain from injury and disease by inhibiting entry of pathogens, immune cells and xenobiotics, including therapeutic drugs, into the brain. His aims were to expand the understanding of BBB biology and identify targets for manipulating BBB permeability for the treatment of BBB&#45;associated neurological diseases and to enhance drug delivery to the brain.&lt;/P&gt;
			                  &lt;HR align=center width=&quot;60%&quot; color=#b33700 SIZE=1&gt;
			                  &lt;BR&gt; &lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles//Remsberg.jpg&quot;
			                  align=right&gt;&lt;B&gt;Connie Remsberg, MD&lt;/B&gt;&lt;BR&gt;
			                  &lt;P style=&quot;MARGIN&#45;LEFT: 12px&quot;&gt;Dr. Connie Remsberg is a pharmacist that completed her Ph.D. in Pharmaceutical Sciences at Washington State University. She  worked with &lt;a href=&quot;lbenet.html&quot;&gt;Dr. Leslie Benet&lt;/a&gt; on clinical studies involving pharmacokinetics, drug transporters, and drug&#45;drug interactions.&lt;/P&gt;
			
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
index.html ./clinpharm/fellowship/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/fellowship/index.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Clinical Pharmacology Training Program ./clinpharm/fellowship/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/fellowship/index.html~</Path>
		<FileBody>
						
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;table border=0 align=right cellpadding=0 cellspacing=0 bgcolor=#eeeeee&gt;
			&lt;tr&gt;&lt;td width=12&gt;&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/common/eeeeee&#45;topleft&#45;12.gif&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td width=12&gt;&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/common/eeeeee&#45;topright&#45;12.gif&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;
			
			&lt;table border=0 cellpadding=2&gt;
			&lt;tr valign=top&gt;&lt;td&gt;
			&lt;li&gt;&lt;a href=&quot;#resfellow&quot;&gt;Research Fellowships&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;#trainprog&quot;&gt;The Training Program&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;#restrain&quot;&gt;Research Training&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;#clintrain&quot;&gt;Clinical Training&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;#didactic&quot;&gt;Didactic Courses &amp; Seminars&lt;/a&gt;
			&lt;/td&gt;&lt;/tr&gt;
			&lt;/table&gt;
			&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
			&lt;tr&gt;&lt;td&gt;&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/common/eeeeee&#45;bottomleft&#45;12.gif&quot;&gt;&lt;/td&gt;&lt;td&gt;&lt;/td&gt;&lt;td&gt;&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/common/eeeeee&#45;bottomright&#45;12.gif&quot;&gt;&lt;/td&gt;&lt;/tr&gt;
			&lt;/table&gt;
			
			&lt;p style=&quot;font&#45;size:13px; color:#003366; margin&#45;left:11px; margin&#45;right:11px;margin&#45;top:11px;&quot;&gt;The Clinical Pharmacology Training Program is accepting  &lt;a href=&quot;/sites/clinpharm.ucsf.edu/files/docs/cpfp&#45;app&#45;2010.pdf&quot;&gt;applications&lt;/a&gt;.&lt;/p&gt;
			
			&lt;a name=&quot;resfellow&quot;&gt;&lt;/a&gt;&lt;b&gt;&lt;span style=&quot;font&#45;variant:small&#45;caps;font&#45;size:12px;font&#45;size:12px;&quot;&gt;Research Fellowships&lt;/span&gt;&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:11px;&quot;&gt;The Division of Clinical Pharmacology and Experimental Therapeutics sponsors postdoctoral research fellowships. Fellowships are supported by the National Institute of General Medical Sciences (NIGMS) and the UCSF Schools of Pharmacy and Medicine. Fellowships are offered only to United States citizens or to individuals who are permanent residents. They are not available to support training for foreign nationals on non&#45;immigrant visas. &lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:11px;&quot;&gt;
			The principal goal of these fellowships is to provide an intensive experience in scientific investigation for 1) board certified physicians (adult and pediatric) in their early postdoctoral years,; 2) PharmDs in their early postdoctoral years, preferably after their general residency training; and 3) PhDs with a clear interest in clinical pharmacology research. 
			&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:11px;&quot;&gt;The University of California, San Francisco, policy states in order to be considered a postdoctoral fellow, one must be a graduate of a medical, allopathic, osteopathic or pharmacy school within the last ten (10) years prior to beginning the fellowship. Applicants are encouraged to apply for a fellowship at least one year prior to the start of a fellowship period, which usually (although not necessarily) begins on July 1 of the academic year. The fellowship usually lasts two years, but may be extended a third year by mutual agreement between fellow and the faculty of the Division.
			&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:11px;&quot;&gt;The UCSF Clinical Pharmacology Postdoctoral Training Program seeks candidates whose experience, teaching, research, or community service has prepared them to contribute to our commitment to diversity and excellence. UCSF is an Equal Opportunity/Affirmative Action Employer. The University undertakes affirmative action to assure equal employment opportunity for underutilized minorities and women, for persons with disabilities, and for covered veterans. All qualified applicants are encouraged to apply, including minorities and women.
			
			
			
			 
			&lt;/p&gt;
			
			
			&lt;a href=&quot;#top&quot;&gt;back to top&lt;/a&gt;&lt;p&gt;
			
			&lt;hr color=black size=1 width=100%&gt;&lt;a name=&quot;trainprog&quot;&gt;&lt;/a&gt;&lt;b&gt;&lt;span style=&quot;font&#45;variant:small&#45;caps;font&#45;size:12px;&quot;&gt;The Training Program&lt;/span&gt;&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:11px;&quot;&gt;The Clinical Pharmacology Fellowship Training Program at UCSF is rigorous, research&#45;intensive and designed specifically to prepare fellows for positions as independent investigators and teachers in academia, industry and regulatory agencies. Since its inception in 1965, approximately 125 fellows have graduated from the program; most of these graduates are actively engaged in academic teaching and research.&lt;/p&gt;
			
			
			&lt;p style=&quot;margin&#45;left:11px;&quot;&gt;We train our fellows using a variety of complimentary modalities, including:&lt;/p&gt;
			
			&lt;ul&gt;
			&lt;li&gt;Mentored research
			&lt;li&gt;More than 75% of the fellowship will be dedicated to conducting research projects (for details, see Research Training below)
			&lt;li&gt;Fellows have a wide spectrum of research opportunities that are focused around a vigorous group of well&#45;funded faculty.
			&lt;/ul&gt;
			
			&lt;p style=&quot;margin&#45;left:11px;&quot;&gt;Didactic coursework designed to provide basic skills in clinical trial design, pharmacokinetics and pharmacogenetics, and ethical issues in clinical research&lt;/p&gt;
			
			&lt;ul&gt;
			&lt;li&gt;Weekly seminars/journal clubs focusing on the discipline of Clinical Pharmacology (for details, see Didactic Courses and Seminars below)
			&lt;li&gt;Shadowing in decision&#45;making committees (e.g., Pharmacy and Therapeutics Committee, Committee on Human Research) 
			&lt;li&gt;Clinical Consultation (for details, see Clinical Training below)
			&lt;li&gt;Clinical Pharmacology and toxicology Consult service
			&lt;li&gt;Poison Center
			&lt;/ul&gt;
			
			&lt;p style=&quot;margin&#45;left:11px;&quot;&gt;Areas of particular research strength at UCSF include:&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;Pharmacogenetic influences on pharmacokinetics and inter&#45;individual response to drug therapy 
			&lt;li&gt;Pediatric clinical pharmacology
			&lt;li&gt;Geriatric clinical pharmacology 
			&lt;li&gt;Drug interactions based on human drug metabolism 
			&lt;li&gt;Many therapeutic areas: respiratory disease, organ transplantation, breast cancer, metabolic disorders, HIV, cardiovascular disease, addiction medicine and psychiatry to name a few.
			&lt;/ul&gt;
			
			&lt;p style=&quot;margin&#45;left:11px;&quot;&gt;&lt;b&gt;Fellowship funding and visas:&lt;/b&gt;&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:22px;&quot;&gt;Fellowship funding comes from an NIGMS T32 training grant.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:22px;&quot;&gt;&lt;u&gt;For fellows supported by NIGMS funds:&lt;/u&gt;&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:33px;&quot;&gt;Fellowships provided by the NIGMS are offered only to United States citizens or to individuals who are permanent residents.  They are not available to support training for foreign nationals on non&#45;immigrant visas.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:33px;&quot;&gt;Participation in the fellowship provided by NIGMS entails a payback agreement, in which fellows are required to devote an amount of time equal to the number of years of stipend support in subsequent academic pursuits.  For further information about this provision, fellowship applicants are encouraged to ask questions of faculty members in the Division or to request information directly from NIGMS.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:33px;&quot;&gt;Physician postdoctoral fellows who have clinical activities at UCSF or its affiliated hospitals are required to receive salary at rates established annually by the University of California Office of the President (UCOP).  UCOP salary rates are approximately $7,000 &#45; $8,000 higher than the previously listed NIH stipend levels, so a source for additional funding will have to be arranged.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:33px;&quot;&gt;PharmDs will be appointed as postdoctoral fellows and be paid at the appropriate NIH stipend level, regardless of whether or not they have clinical activities.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:33px;&quot;&gt;NIGMS stipend salary levels are determined by the number of years of relevant postdoctoral training at the time of the appointment into the fellowship.  The following table shows the stipend levels effective July 1, 2010.&lt;/p&gt;
					
			&lt;table border=&quot;0&quot; cellpadding=3 cellspacing=1 style=&quot;margin&#45;left:33px;&quot;&gt;
			
			&lt;TR valign=bottom align=center bgcolor=&quot;#003366&quot;&gt; 
			&lt;Td&gt;&lt;font color=white&gt;Number of post&lt;br&gt;graduate years of&lt;br&gt;relevant experience&lt;/font&gt;&lt;/Td&gt;&lt;Td&gt;&lt;font color=white&gt;NIH annual stipend&lt;br&gt;
			rate FY 2010&lt;/font&gt;&lt;/Td&gt;
			&lt;/TR&gt;
																														include('/data/templates/new/bottom&#45;2008.php');
		</FileBody>
	</node>
	<node>
		<Fname>
Related Fellowship Programs ./clinpharm/fellowship/related.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/fellowship/related.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;b&gt;Medical Toxicology Training Program&lt;/b&gt; &#45; &lt;i&gt;coming soon&lt;/i&gt;
			&lt;/ul&gt;
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Research Fellowships ./clinpharm/fellowship/research_fellowships.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/fellowship/research_fellowships.html</Path>
		<FileBody>
						
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;div style=&quot;float:right;&quot;&gt;
			&lt;a href=&quot;https://ucsf.co1.qualtrics.com/SE/?SID=SV_1SUQUQTNzJxV8Sp&quot;&gt;
			&lt;button type=&quot;button&quot; style=&quot;border:1px solid #ccc;&quot;&gt;Apply Now&lt;/button&gt;&lt;/a&gt;
			&lt;/div&gt;&lt;p class=&quot;introduction&quot;&gt;The Clinical Pharmacology Training Program is accepting  &lt;a href=&quot;/sites/clinpharm.ucsf.edu/files/docs/cpfp&#45;app&#45;2010.pdf&quot;&gt;applications&lt;/a&gt;.&lt;/p&gt;
			
			&lt;h4&gt;Research Fellowships&lt;/h4&gt;
			
			&lt;p&gt;The Division of Clinical Pharmacology and Experimental Therapeutics sponsors postdoctoral research fellowships. Fellowships are supported by the National Institute of General Medical Sciences (NIGMS) and the UCSF Schools of Pharmacy and Medicine. Fellowships are offered only to United States citizens or to individuals who are permanent residents. They are not available to support training for foreign nationals on non&#45;immigrant visas. &lt;/p&gt;
			
			&lt;p&gt;
			The principal goal of these fellowships is to provide an intensive experience in scientific investigation for 1) board certified physicians (adult and pediatric) in their early postdoctoral years,; 2) PharmDs in their early postdoctoral years, preferably after their general residency training; and 3) PhDs with a clear interest in clinical pharmacology research. 
			&lt;/p&gt;
			
			&lt;p&gt;The University of California, San Francisco, policy states in order to be considered a postdoctoral fellow, one must be a graduate of a medical, allopathic, osteopathic or pharmacy school within the last ten (10) years prior to beginning the fellowship. Applicants are encouraged to apply for a fellowship at least one year prior to the start of a fellowship period, which usually (although not necessarily) begins on July 1 of the academic year. The fellowship usually lasts two years, but may be extended a third year by mutual agreement between fellow and the faculty of the Division.
			&lt;/p&gt;
			
			&lt;p&gt;The UCSF Clinical Pharmacology Postdoctoral Training Program seeks candidates whose experience, teaching, research, or community service has prepared them to contribute to our commitment to diversity and excellence. UCSF is an Equal Opportunity/Affirmative Action Employer. The University undertakes affirmative action to assure equal employment opportunity for underutilized minorities and women, for persons with disabilities, and for covered veterans. All qualified applicants are encouraged to apply, including minorities and women.
			
			
			
			 
			&lt;/p&gt;
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Research Training ./clinpharm/fellowship/research_training.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/fellowship/research_training.html</Path>
		<FileBody>
			
			
			
			
			&lt;p&gt;Our fellows are expected to develop expertise in one or more of the following research areas:&lt;/p&gt;
			
			&lt;ol type=A&gt;
			&lt;li&gt;Fundamental research on principles or mechanisms of drug action or toxicity.
			&lt;li&gt;Drug discovery and development (including post&#45;marketing surveillance).
			&lt;li&gt;Pharmacogenomics. 
			&lt;li&gt;Health Services Research (including studies of drug use and effects, pharmacoepidemiology, optimizing drug use).
			&lt;li&gt;In addition to specific research skills such as (a) design of clinical trials, (b) statistical analysis and research criticism skills, (c) scientific writing, including grant writing, and (d) familiarity with activities of institutional review boards for human research.
			&lt;/ol&gt;
			
			
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
The Training Program ./clinpharm/fellowship/training_program.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/fellowship/training_program.html</Path>
		<FileBody>
			
			
			&lt;p&gt;The Clinical Pharmacology Fellowship Training Program at UCSF is rigorous, research&#45;intensive and designed specifically to prepare fellows for positions as independent investigators and teachers in academia, industry and regulatory agencies. Since its inception in 1965, approximately 125 fellows have graduated from the program; most of these graduates are actively engaged in academic teaching and research.&lt;/p&gt;
			
			
			&lt;p&gt;We train our fellows using a variety of complimentary modalities, including:&lt;/p&gt;
			
			&lt;ul&gt;
			&lt;li&gt;Mentored research
			&lt;li&gt;More than 75% of the fellowship will be dedicated to conducting research projects (for details, see Research Training below)
			&lt;li&gt;Fellows have a wide spectrum of research opportunities that are focused around a vigorous group of well&#45;funded faculty.
			&lt;/ul&gt;
			
			&lt;p&gt;Didactic coursework designed to provide basic skills in clinical trial design, pharmacokinetics and pharmacogenetics, and ethical issues in clinical research&lt;/p&gt;
			
			&lt;ul&gt;
			&lt;li&gt;Weekly seminars/journal clubs focusing on the discipline of Clinical Pharmacology (for details, see Didactic Courses and Seminars below)
			&lt;li&gt;Shadowing in decision&#45;making committees (e.g., Pharmacy and Therapeutics Committee, Committee on Human Research) 
			&lt;li&gt;Clinical Consultation (for details, see Clinical Training below)
			&lt;li&gt;Clinical Pharmacology and toxicology Consult service
			&lt;li&gt;Poison Center
			&lt;/ul&gt;
			
			&lt;p&gt;Areas of particular research strength at UCSF include:&lt;/p&gt;
			&lt;ul&gt;
			&lt;li&gt;Pharmacogenetic influences on pharmacokinetics and inter&#45;individual response to drug therapy 
			&lt;li&gt;Pediatric clinical pharmacology
			&lt;li&gt;Geriatric clinical pharmacology 
			&lt;li&gt;Drug interactions based on human drug metabolism 
			&lt;li&gt;Many therapeutic areas: respiratory disease, organ transplantation, breast cancer, metabolic disorders, HIV, cardiovascular disease, addiction medicine and psychiatry to name a few.
			&lt;/ul&gt;
			
			&lt;p&gt;&lt;b&gt;Fellowship funding and visas:&lt;/b&gt;&lt;/p&gt;
			
			&lt;p&gt;Fellowship funding comes from an NIGMS T32 training grant.&lt;/p&gt;
			
			&lt;p&gt;&lt;u&gt;For fellows supported by NIGMS funds:&lt;/u&gt;&lt;/p&gt;
			
			&lt;p&gt;Fellowships provided by the NIGMS are offered only to United States citizens or to individuals who are permanent residents.  They are not available to support training for foreign nationals on non&#45;immigrant visas.&lt;/p&gt;
			
			&lt;p&gt;Participation in the fellowship provided by NIGMS entails a payback agreement, in which fellows are required to devote an amount of time equal to the number of years of stipend support in subsequent academic pursuits.  For further information about this provision, fellowship applicants are encouraged to ask questions of faculty members in the Division or to request information directly from NIGMS.&lt;/p&gt;
			
			&lt;p&gt;Physician postdoctoral fellows who have clinical activities at UCSF or its affiliated hospitals are required to receive salary at rates established annually by the University of California Office of the President (UCOP).  UCOP salary rates are approximately $7,000 &#45; $8,000 higher than the previously listed NIH stipend levels, so a source for additional funding will have to be arranged.&lt;/p&gt;
			
			&lt;p&gt;PharmDs will be appointed as postdoctoral fellows and be paid at the appropriate NIH stipend level, regardless of whether or not they have clinical activities.&lt;/p&gt;
			
			&lt;p&gt;NIGMS stipend salary levels are determined by the number of years of relevant postdoctoral training at the time of the appointment into the fellowship.  The following table shows the stipend levels effective July 1, 2010.&lt;/p&gt;
					
			&lt;table border=&quot;0&quot; cellpadding=3 cellspacing=1 style=&quot;margin&#45;left:33px;&quot;&gt;
			
			&lt;TR valign=bottom align=center&gt; 
			&lt;th&gt;Number of post&#45;graduate years of relevant experience&lt;/th&gt;&lt;th&gt;NIH annual stipend
			rate FY 2010&lt;/th&gt;
			&lt;/TR&gt;
			
			
			
			&lt;TR align=center valign=top &gt;
			&lt;td&gt;0&lt;/td&gt;
			&lt;td&gt;$37,740&lt;/td&gt;
			&lt;/tr&gt;
			&lt;TR align=center valign=top &gt;
			&lt;td class=&quot;other&quot;&gt;1&lt;/td&gt;
			&lt;td class=&quot;other&quot;&gt;$39,756&lt;/td&gt;
			&lt;/tr&gt;
			&lt;TR align=center valign=top &gt;
			&lt;td&gt;2&lt;/td&gt;
			&lt;td&gt;$42,624&lt;/td&gt;
			&lt;/tr&gt;
			&lt;TR align=center valign=top &gt;
			&lt;td class=&quot;other&quot;&gt;3&lt;/td&gt;
			&lt;td class=&quot;other&quot;&gt;$44,304&lt;/td&gt;
			&lt;/tr&gt;
			&lt;TR align=center valign=top &gt;
			&lt;td&gt;4&lt;/td&gt;
			&lt;td&gt;$45,960&lt;/td&gt;
			&lt;/tr&gt;
			&lt;TR align=center valign=top &gt;
			&lt;td class=&quot;other&quot;&gt;5&lt;/td&gt;
			&lt;td class=&quot;other&quot;&gt;$47,940&lt;/td&gt;
			&lt;/tr&gt;
			&lt;TR align=center valign=top &gt;
			&lt;td&gt;6&lt;/td&gt;
			&lt;td&gt;$49,836&lt;/td&gt;
			&lt;/tr&gt;
			&lt;TR align=center valign=top&gt;
			&lt;td class=&quot;other&quot;&gt;7+&lt;/td&gt;
			&lt;td class=&quot;other&quot;&gt;$52,068&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/table&gt;&lt;br&gt;
			
			&lt;p&gt;&lt;u&gt;For fellows supported by other (non&#45;NIGMS) funds:&lt;/u&gt;&lt;/p&gt;
			
			&lt;p&gt;All foreign fellows who are accepted into the fellowship program (and who will be paid by UCSF or their home governments or institutions) must apply for J&#45;1 exchange visitor status.&lt;/p&gt;
			
			&lt;p&gt;Foreign fellows who are physicians and have clinical responsibilities under supervision must apply for ECFMG sponsored J&#45;1 exchange visitor status. To be eligible for ECFMG J&#45;1 sponsorship for clinical training, one must meet ECFMG's requirements. For more information, visit ECFMG website at: &lt;a href=&quot;http://www.ecfmg.org/evsp/j1fact.html&quot; target=&quot;_blank&quot;&gt;http://www.ecfmg.org/evsp/j1fact.html&lt;/a&gt;&lt;/p&gt;
			
			&lt;p&gt;If fellows have obtained only a J1 visa (rather than the ECFMG J&#45;1 visa), they may only observe patient care and may not provide patient care even with supervision.&lt;/p&gt;
			
			
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Internal ./clinpharm/internal/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/internal/index.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
applicants.html ./clinpharm/medtox/applicants.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/medtox/applicants.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Medical Toxicology Curriculum ./clinpharm/medtox/curriculum.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/medtox/curriculum.html</Path>
		<FileBody>
						
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;div style=&quot;margin&#45;left:12px;margin&#45;right:12px;border:solid;border&#45;color:#99bbcc;border&#45;width:1px;padding:10px;border&#45;radius:15px&quot;&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;#traditional&quot;&gt;Traditional Track&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;#didactics&quot;&gt;Didactics&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;#electives&quot;&gt;Electives&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			&lt;/div&gt;
			&lt;br /&gt;
			&lt;a name=&quot;traditional&quot;&gt;&lt;/a&gt;&lt;h4&gt;Medical Toxicology Curriculum Summary (Traditional Track)&lt;/h4&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;&lt;b&gt;Year I&lt;/b&gt;&lt;br&gt;&amp;nbsp;&lt;br&gt;
			
			The toxicology fellow spends 12 months running the Clinical Toxicology Consulting Service at San Francisco General Hospital (SFGH) and the California Poison Control System &#45; San Francisco Division (CPCS&#45;SF) under the supervision of the medical toxicology program attending physicians.  The fellow develops core knowledge content and confidence in assessing and treating poisoning and drug overdose through bedside consultations at SFGH and telephone consultations at the CPCS&#45;SF.&lt;/p&gt;
			
			&lt;table border=&quot;0&quot; cellpadding=3 cellspacing=1 style=&quot;margin&#45;left:24px;&quot;&gt;
			
			&lt;TR valign=bottom&gt;
			&lt;td colspan=13&gt;&lt;i&gt;example&lt;/i&gt;&lt;/td&gt;
			&lt;/tr&gt;
			
			&lt;tr valign=bottom align=center&gt; 
			&lt;th&gt;&lt;b&gt;Month&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Jul&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Aug&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Sep&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Oct&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Nov&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Dec&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Jan&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Feb&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Mar&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Apr&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;May&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Jun&lt;/b&gt;&lt;/th&gt;
			&lt;/tr&gt;
									
						&lt;td rowspan=2&gt;Rotation&lt;/td&gt;&lt;td&gt;CTS&lt;/td&gt;&lt;td&gt;TICR&lt;/td&gt;&lt;td&gt;TICR&lt;/td&gt;&lt;td&gt;LM&lt;/td&gt;&lt;td&gt;Res&lt;/td&gt;&lt;td&gt;Res&lt;/td&gt;&lt;td&gt;CTS&lt;/td&gt;&lt;td&gt;OCP&lt;/td&gt;&lt;td&gt;FT&lt;/td&gt;&lt;td&gt;CLP&lt;/td&gt;&lt;td&gt;CTS&lt;/td&gt;&lt;td&gt;CTS&lt;/td&gt;
			&lt;/tr&gt;
			
						include('/data/templates/new/bottom&#45;2008.php');
		</FileBody>
	</node>
	<node>
		<Fname>
Medical Toxicology Curriculum ./clinpharm/medtox/didactics.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/medtox/didactics.html</Path>
		<FileBody>
						
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;h4&gt;Didactics&lt;/h4&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;Fellows partake in a number of regularly scheduled educational conferences.&lt;/p&gt;
			
			&lt;table border=&quot;0&quot; cellpadding=3 cellspacing=1 style=&quot;margin&#45;left:24px;&quot;&gt;
			
			&lt;TR valign=bottom align=center&gt; 
			&lt;th&gt;&lt;b&gt;Conference&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Frequency&lt;/b&gt;&lt;/th&gt;
			&lt;/TR&gt;
			
			
			
			&lt;TR valign=top&gt;
			&lt;td&gt;Toxicology Attending Rounds&lt;/td&gt;&lt;td&gt;Daily&lt;/td&gt;
			&lt;/tr&gt;
			
			
			&lt;TR valign=top class=&quot;other&quot;&gt;
			&lt;td class=&quot;other&quot;&gt;Toxicology Grand Rounds&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;Every Tuesday, 8:30&#45;10 AM&lt;/td&gt;
			&lt;/tr&gt;
			
			
			&lt;TR valign=top&gt;
			&lt;td&gt;Statewide Teleconference&lt;/td&gt;&lt;td&gt;Every other Monday, 12 PM&lt;/td&gt;
			&lt;/tr&gt;
			
			
			&lt;TR valign=top class=&quot;other&quot;&gt;
			&lt;td class=&quot;other&quot;&gt;Journal Club&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;Every other Monday, 12 PM&lt;/td&gt;
			&lt;/tr&gt;
			
			
			&lt;TR valign=top&gt;
			&lt;td&gt;Fellows Lecture Series&lt;/td&gt;&lt;td&gt;Every Tuesday, 12&#45;1 PM&lt;/td&gt;
			&lt;/tr&gt;
			
			
			&lt;TR valign=top class=&quot;other&quot;&gt;
			&lt;td class=&quot;other&quot;&gt;Occupational and Environmental Med Clinic&lt;/td&gt;&lt;td class=&quot;other&quot;&gt;Selected Thursdays, AM&lt;/td&gt;
			&lt;/tr&gt;
			
			
			&lt;TR valign=top&gt;
			&lt;td&gt;Clinical Pharmacology Research Seminar&lt;/td&gt;&lt;td&gt;Selected Thursdays, PM&lt;/td&gt;
			&lt;/tr&gt;
			
			&lt;/table&gt;&lt;p&gt;
			
			&lt;b&gt;Toxicology Attending Rounds&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;Daily attending rounds are conducted by the faculty of the medical toxicology fellowship program, in conjunction with the fellows, rotating residents, and medical and pharmacy students.  During these sessions, fellows assist the residents and students in presenting cases that pose challenges in the diagnosis, clinical management, and treatment of poisonings.  Fellows present both cases called into the Poison Control Center as well as those seen directly at the bedside at San Francisco General Hospital.  Daily rounds provide an opportunity for the faculty to answer questions and to provide general teaching points.&lt;/p&gt;
			
			&lt;b&gt;Toxicology Grand Rounds&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;Fellows present interesting cases from the prior week for further discussion with all medical toxicology faculty members and members of the laboratory staff at SFGH. In the ensuing discussion, faculty members provide constructive feedback about the management of each case.  Fellows are expected to review the current literature relating to the management of each case.  This may involve searching PubMed and other resources for pertinent case reports, original research and review articles.&lt;/p&gt;
			
			&lt;b&gt;Statewide Teleconference&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;Statewide Teleconference is a unique experience that allows for discussion and collaboration with the Fresno, Sacramento and San Diego Divisions of the California Poison Control System.  The teleconference takes place every other week and is hosted by each division on a rotating basis. Fellows present 6&#45;8 interesting cases, and lively debate typically ensues.&lt;/p&gt;
			
			&lt;b&gt;Journal Club&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;Articles are selected from the current scientific literature.  Fellows are assigned one article for presentation.  Journal club offers the fellows an opportunity to critically evaluate the current literature, and to contemplate study design and execution for their own research projects.&lt;/p&gt;
			
			&lt;b&gt;Fellows Lecture Series&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;Medical toxicology faculty, poison center staff, invited lecturers and senior fellows give ongoing lectures designed for the junior fellows.  Lectures topics are selected based on the required core content of medical toxicology.  A schedule is provided at the beginning of each academic year, and fellows are required to attend all lectures.&lt;/p&gt;
			
			&lt;b&gt;Occupational and Environmental Medicine Clinic&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;Fellows see patients referred to this clinic for toxicology related exposures. Cases include both occupational and environmental exposures. Some families and pediatric cases are seen as referrals from the Pediatric Environmental Health Specialty Unit. Industrial hygiene and nursing students also participate in patient evaluations, as does our faculty Industrial Hygienist. Common presentations include: exposures to mold in the indoor environment; elevated blood or urine levels of metals such as arsenic or mercury; respiratory symptoms associated with inhaled allergens, dusts, or fumes; solvent and pesticide exposures.&lt;/p&gt;
			
			&lt;b&gt;Clinical Pharmacology Research Seminar&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;Organized and led by Dr. Neal Benowitz, this seminar introduces the fellows to important concepts of pharmacology, pharmacokinetics and pharmacogenomics.&lt;/p&gt;
			
			
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Medical Toxicology Curriculum ./clinpharm/medtox/electives.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/medtox/electives.html</Path>
		<FileBody>
						
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			&lt;h4&gt;Electives&lt;/h4&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;During the second year of training the following 1&#45;month electives are available.&lt;/p&gt;
			
			&lt;b&gt;Childhood Lead Poisoning and Prevention&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;Fellows participate in lectures and meetings related to the functions of the CLPPB and may assist with the investigation of lead poisoning.  Under the supervision of Dr. Valerie Charlton and the DPH staff they gain a greater understanding of the diagnosis and management of patients with exposure to lead.&lt;/p&gt;
			
			&lt;b&gt;Forensic Toxicology&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;Fellows participate in meetings and lectures related to the functions of the San Francisco Medical Examiner's Office.  Under the supervision of Amy Hart MD and the Medical Examiner's staff, fellows review results of toxicology test performed in the forensic lab.  They also have the opportunity to tour the laboratories and learn about analytical techniques for drugs of abuse and comprehensive drug testing, as well as procedures related to chain of custody of biologic specimens.&lt;/p&gt;
			
			&lt;b&gt;Laboratory Medicine&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;Fellows participate in lectures and meetings related to the function of the Toxicology Laboratory at San Francisco General Hospital.   Under the supervision of Alan Wu, PhD they develop a greater understanding of basic analytical techniques for drugs of abuse and comprehensive drug screening including immunologic based urine screening techniques, the use of GC&#45;MS, liquid chromatography, flame photometry, co&#45;oximetry and others.&lt;/p&gt;
			
			&lt;b&gt;Lawrence Livermore National Laboratory&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;During this rotation, fellows participate in the assessment of occupational exposures unique to the setting of the Lawrence Livermore National Laboratory.  These may include radiation exposures, gas and heavy metal exposures among others.&lt;/p&gt;
			
			&lt;b&gt;Medical Intensive Care Unit&lt;/b&gt;&lt;br&gt;
			&lt;i&gt;Required for those individuals whose primary specialty training did not include a month of adult intensive care (e.g., those trained in pediatrics, psychiatry or laboratory medicine)&lt;/i&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;During this rotation fellows develop a better understanding of the management of adult critical care patients.  They participate in lectures, case conferences, work rounds and attending rounds.  Fellows are expected to research topics of interest for the housestaff and provide a short series of lectures on poisonings.&lt;/p&gt;
			
			&lt;b&gt;Pediatric Environmental Health Specialty Unit (PEHSU)&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;Fellows participate in lectures and meetings related to functions of the PEHSU and will assist with telephone response and case investigations.  Under the supervision of Dr. John Balmes, fellows develop a further understanding of the environmental hazards within the pediatric community.  They may also assist in the development of printed materials for the public.&lt;/p&gt;
			
			&lt;b&gt;Pediatric Intensive Care Unit&lt;/b&gt;&lt;br&gt;
			&lt;i&gt;Required for those individuals whose primary specialty training did not include a month of pediatric intensive care (e.g., those trained in internal medicine, psychiatry or laboratory medicine)&lt;/i&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;During this rotation, fellows develop a better understanding of the management of pediatric critical care patients.  They participate in lectures, case conferences, work rounds and attending rounds.  It is expected that they research topics of interest for the house staff and provide a short series of lectures on poisonings.&lt;/p&gt;
			
			&lt;b&gt;Occupational Clinical Practice&lt;/b&gt;&lt;br&gt;
			&lt;i&gt;Required for all fellows&lt;/i&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;During this rotation fellows participate in the evaluation and treatment of patients with occupational and environmental illness and injury.  Under the supervision of Dr. Richard Cohen, fellows develop their knowledge base in the area of occupational toxicology, including the diagnosis, management and treatment of these patients.&lt;/p&gt;
			
			
			
			
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Medical Toxicology Faculty &amp;amp; Staff ./clinpharm/medtox/facstaff.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/medtox/facstaff.html</Path>
		<FileBody>
						
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;b&gt;Faculty&lt;/b&gt;
			
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/people/kolson.html&quot;&gt;Kent R. Olson, MD&lt;/a&gt;, Medical Director, California Poison Control Center, SF Division&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/people/csmollin.html&quot;&gt;Craig G. Smollin, MD&lt;/a&gt;, Fellowship Director&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/people/nbenowitz.html&quot;&gt;Neal Benowitz, MD&lt;/a&gt;&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/people/pblanc.html&quot;&gt;Paul Blanc, MD&lt;/a&gt;&lt;/li&gt;
			
			&lt;li&gt;&lt;a href=&quot;/people/tkearney.html&quot;&gt;Thomas Kearney, PharmD&lt;/a&gt;, Managing Director, California Poison Control Center, SF Division&lt;/li&gt;
			&lt;li&gt;&lt;a href=&quot;/people/awu.html&quot;&gt;Alan Wu, PhD&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Administrative Staff&lt;/b&gt;
			
			&lt;ul&gt;
			
			&lt;li&gt;&lt;a href=&quot;mailto:phiatt@calpoison.org&quot;&gt;Patty Hiatt&lt;/a&gt;&lt;/li&gt;
			&lt;/ul&gt;
			
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Medical Toxicology Fellows ./clinpharm/medtox/fellows.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/medtox/fellows.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Medical Toxicology Training Program ./clinpharm/medtox/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/medtox/index.html</Path>
		<FileBody>
						
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;p style=&quot;font&#45;size:13px; color:#003366; margin&#45;left:11px; margin&#45;right:11px;margin&#45;top:11px;&quot;&gt;The Medical Toxicology Training Program is accepting  &lt;a href=&quot;../docs/medtox&#45;app&#45;2013.pdf&quot;&gt;applications&lt;/a&gt;.&lt;/p&gt;
			
			&lt;img style=&quot;display: block; margin&#45;left: auto; margin&#45;right: auto;&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/sfgh&#45;heart600.jpg&quot;&gt;&lt;br clear=all&gt;
			
			&lt;b&gt;The Subspecialty of Medical Toxicology&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Medical toxicology focuses on the diagnosis, management and prevention of poisoning due to drugs, occupational and environmental toxins and biological agents.  Examples of exposures commonly evaluated by medical toxicologists include acute drug overdoses, envenomations, ingestions of food borne or plant and mushroom toxins, hazardous exposures to chemical products, and the management of drug withdrawal syndromes.   Medical toxicologists practice in a variety of professional settings including the direct treatment and consultation of acutely poisoned patients in emergency departments or intensive care units, poison control center management, industry and commerce, as well as government regulatory bodies (e.g., CDC, FDA, OSHA , EPA).&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Medical toxicology is officially recognized as a medical subspecialty by the American Board of Medical Specialties. In July of 2000, the Accreditation Council for Graduate Medical Education (ACGME) established criteria for accreditation of medical toxicology fellowships.  These criteria are rigorous and attempt to establish a baseline level of consistency in training among the various training programs.  There are currently 29 ACGME approved medical toxicology programs in the United States.&lt;/p&gt;
			
			&lt;b&gt;Medical Toxicology at UCSF and San Francisco General Hospital&lt;/b&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;The UCSF medical toxicology fellowship received full accreditation by the ACGME in 2001, and is currently certified through the year 2014.  It is a two&#45;year program primarily based at the San Francisco Division of the California Poison Control System (CPCS) and San Francisco General Hospital (SFGH).  The program is designed to develop competent clinical toxicology practitioners, educators, researchers and administrators for academic, clinical, or industry settings, and to prepare its graduates for successful completion of the board certification examination in Medical Toxicology.  Fellows play an integral role in the education of medical students, pharmacy students, and residents in emergency medicine and other specialties rotating through the poison control center, and through clinical interactions at the bedside at SFGH.&lt;/p&gt;
			
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
Medical Toxicology Curriculum ./clinpharm/medtox/tradtrack.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/medtox/tradtrack.html</Path>
		<FileBody>
						
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			
			&lt;br /&gt;
			&lt;a name=&quot;traditional&quot;&gt;&lt;/a&gt;&lt;h4&gt;Medical Toxicology Curriculum Summary (Traditional Track)&lt;/h4&gt;
			
			&lt;p style=&quot;margin&#45;left:12px;&quot;&gt;&lt;b&gt;Year I&lt;/b&gt;&lt;br&gt;&amp;nbsp;&lt;br&gt;
			
			The toxicology fellow spends 12 months running the Clinical Toxicology Consulting Service at San Francisco General Hospital (SFGH) and the California Poison Control System &#45; San Francisco Division (CPCS&#45;SF) under the supervision of the medical toxicology program attending physicians.  The fellow develops core knowledge content and confidence in assessing and treating poisoning and drug overdose through bedside consultations at SFGH and telephone consultations at the CPCS&#45;SF.&lt;/p&gt;
			
			&lt;table border=&quot;0&quot; cellpadding=3 cellspacing=1 style=&quot;margin&#45;left:24px;&quot;&gt;
			
			&lt;TR valign=bottom&gt;
			&lt;td colspan=13&gt;&lt;i&gt;example&lt;/i&gt;&lt;/td&gt;
			&lt;/tr&gt;
			
			&lt;tr valign=bottom align=center&gt; 
			&lt;th&gt;&lt;b&gt;Month&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Jul&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Aug&lt;/b&gt;&lt;/font&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Sep&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Oct&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Nov&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Dec&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Jan&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Feb&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Mar&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Apr&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;May&lt;/b&gt;&lt;/th&gt;&lt;th&gt;&lt;b&gt;Jun&lt;/b&gt;&lt;/th&gt;
			&lt;/tr&gt;
									
						&lt;td rowspan=2&gt;Rotation&lt;/td&gt;&lt;td&gt;CTS&lt;/td&gt;&lt;td&gt;TICR&lt;/td&gt;&lt;td&gt;TICR&lt;/td&gt;&lt;td&gt;LM&lt;/td&gt;&lt;td&gt;Res&lt;/td&gt;&lt;td&gt;Res&lt;/td&gt;&lt;td&gt;CTS&lt;/td&gt;&lt;td&gt;OCP&lt;/td&gt;&lt;td&gt;FT&lt;/td&gt;&lt;td&gt;CLP&lt;/td&gt;&lt;td&gt;CTS&lt;/td&gt;&lt;td&gt;CTS&lt;/td&gt;
			&lt;/tr&gt;
			
						include('/data/templates/new/bottom&#45;2008.php');
		</FileBody>
	</node>
	<node>
		<Fname>
Administration ./clinpharm/medtox/admin/fellows.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/medtox/admin/fellows.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Administration ./clinpharm/medtox/admin/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/medtox/admin/index.html</Path>
		<FileBody>
			
		</FileBody>
	</node>
	<node>
		<Fname>
Administration ./clinpharm/medtox/admin/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/medtox/admin/index.html~</Path>
		<FileBody>
			
		</FileBody>
	</node>
	<node>
		<Fname>
Log In ./clinpharm/medtox/admin/login.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/medtox/admin/login.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
results.html ./clinpharm/medtox/admin/results.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/medtox/admin/results.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
success.html ./clinpharm/medtox/admin/success.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/medtox/admin/success.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
$custom[entity] Search ./clinpharm/news/search.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/news/search.html</Path>
		<FileBody>
			/* &lt;![CDATA[ */
			
			#ucsfheadercontainer {
			  width: 100%;
			  background&#45;color: #000000;
			}
			td{
			    border:hidden;
			padding:1px;
			}
			
			
			/* ]]&gt; */
					</FileBody>
	</node>
	<node>
		<Fname>
Division Contact Information ./clinpharm/people/admin.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/admin.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;table align=center border=&quot;0&quot; cellpadding=2&gt;
			&lt;TR vAlign=top&gt; 
			&lt;th&gt;&lt;b&gt;Name&lt;/b&gt;&lt;/th&gt;
			&lt;th&gt;&lt;b&gt;Physical Address&lt;/b&gt;&lt;/th&gt;
			&lt;th&gt;&lt;b&gt;Mailing Address&lt;/b&gt;&lt;/th&gt;
			&lt;/TR&gt;
			&lt;TR vAlign=top bgcolor=#eeeeee&gt;
			  &lt;TD&gt;&lt;b&gt;UCSF Division of Clinical Pharmacology &amp;amp; Experimental Therapeutics&lt;/b&gt;&lt;/td&gt;
			  &lt;td bgcolor=#CCCC66&gt;1550 &#45; 4th St., Mission Bay 584&lt;BR&gt;
			University of California, San Francisco&lt;BR&gt;
			San Francisco, CA. 94143 &#45; 2911&lt;br&gt;
			Fax: (415) 514&#45;4365&lt;/td&gt;
			  &lt;td bgcolor=#CBDEEC&gt;UCSF Division of Clinical Pharmacology &amp;amp; Experimental Therapeutics&lt;br&gt;
			San Francisco, CA 94143&#45;2911&lt;/TD&gt;
			&lt;/TR&gt;
			&lt;TR vAlign=top&gt; 
			&lt;td class=&quot;other&quot;&gt;
			&lt;B&gt;Neal Benowitz, MD&lt;/B&gt;&lt;br&gt;
			Chief of Division&lt;/td&gt;
			&lt;TD class=&quot;other&quot;&gt;1001 Potrero Ave, SFGH 30&lt;br&gt;
			San Francisco CA 94143&lt;br&gt;
			415&#45;206&#45;8324
			&lt;/TD&gt;
			&lt;TD class=&quot;other&quot;&gt;UCSF School of Medicine&lt;br&gt;
			
			&lt;a href=&quot;mailto:nbenowitz@medsfgh.ucsf.edu&quot;&gt;nbenowitz@medsfgh.ucsf.edu&lt;/a&gt;
			&lt;/td&gt;
			&lt;/TR&gt;
			
			&lt;TR vAlign=top&gt; 
			&lt;TD bgcolor=eeeeee&gt;
			&lt;B&gt;Jenny Fowler&lt;/B&gt;&lt;br&gt;
			Division Administrator&lt;/td&gt;
			&lt;TD bgcolor=#CCCC66&gt;Box 0846 , 1001 Potrero Ave, SFGH 5 5G6&lt;br&gt;
			University of California, San Francisco&lt;br&gt;
			San Francisco, CA. 94143 &#45; 0846 &lt;br&gt;
			415&#45;206&#45;4118
			&lt;/TD&gt;
			&lt;td bgcolor=#CBDEEC&gt;
			&lt;a href=&quot;mailto:jfowler@medsfgh.ucsf.edu&quot;&gt;jfowler@medsfgh.ucsf.edu&lt;/a&gt;
			&lt;/td&gt;
			&lt;/TR&gt;
			&lt;tr&gt;&lt;th colspan=&quot;3&quot;&gt;Fellowship Program Administration&lt;/th&gt;&lt;/tr&gt;
			
			&lt;TR vAlign=top&gt; 
			&lt;td class=&quot;other&quot;&gt;
			&lt;B&gt;Esteban Gonz&amp;aacute;lez Burchard, MD&lt;/B&gt;&lt;br&gt;
			Assistant Professor, Bioengineering &amp;amp; Therapeutic Sciences and Medicine&lt;br&gt;
			Director, Clinical Pharmacology Fellowship Program&lt;/td&gt;
			&lt;TD class=&quot;other&quot;&gt;Rock Hall, Mission Bay&lt;br&gt;
			1550 4&lt;sup&gt;th&lt;/sup&gt; Street, RH&#45;584C&lt;br&gt;
			San Francisco, CA 94158&lt;br&gt;
			(415) 514&#45;9677
			&lt;/TD&gt;
			&lt;TD class=&quot;other&quot;&gt;UCSF Department of Bioengineering &amp;amp; Therapeutic Sciences&lt;br&gt;
			San Francisco, CA 94143&#45;2911&lt;br&gt;
			&lt;a href=&quot;mailto:esteban@sfgh.ucsf.edu&quot;&gt;esteban@sfgh.ucsf.edu&lt;/a&gt;
			&lt;/td&gt;
			&lt;/TR&gt;
			
			&lt;TR vAlign=top&gt; 
			&lt;TD bgcolor=eeeeee&gt;
			&lt;B&gt;Leslie Carstensen Floren, PharmD&lt;/B&gt;&lt;br&gt;
			Assistant Adjunct Professor of Bioengineering &amp;amp; Therapeutic Sciences&lt;br&gt;
			Co&#45;Director, Clinical Pharmacology Fellowship Program&lt;/td&gt;
			&lt;TD bgcolor=#CCCC66&gt;Byers Hall, Mission Bay&lt;br&gt;
			1700 4&lt;sup&gt;th&lt;/sup&gt; Street, BH&#45;216D&lt;br&gt;
			San Francisco, CA 94158&lt;br&gt;
			(415) 514&#45;3559
			&lt;/TD&gt;
			&lt;td bgcolor=#CBDEEC&gt;UCSF Department of Bioengineering &amp;amp; Therapeutic Sciences&lt;br&gt;
			San Francisco, CA 94143&#45;2911&lt;br&gt;
			&lt;a href=&quot;mailto:leslie.floren@ucsf.edu&quot;&gt;leslie.floren@ucsf.edu&lt;/a&gt;
			&lt;/td&gt;
			&lt;/TR&gt;
			
			&lt;TR vAlign=top&gt; 
			&lt;td class=&quot;other&quot;&gt;&lt;b&gt;Christine Mok &lt;/b&gt;&lt;br&gt;
			Administrative Analyst&lt;/td&gt;
			&lt;td class=&quot;other&quot;&gt;1550 &#45; 4th St., Mission Bay 584&lt;BR&gt;
			University of California, San Francisco&lt;BR&gt;
			San Francisco, CA. 94143 &#45; 2911&lt;br&gt;
			(415) 514&#45;4273&lt;/td&gt;
			&lt;td  class=&quot;other&quot;&gt;UCSF Division of Clinical Pharmacology &amp;amp; Experimental Therapeutics&lt;br&gt;
			San Francisco, CA 94143&#45;2911&lt;br&gt;
			&lt;a href=&quot;mailto:ptarr@medsfgh.ucsf.edu&quot;&gt;christine.mok@ucsf.edu&lt;/a&gt;&lt;/TD&gt;
			&lt;/TR&gt;
			
			&lt;/table&gt;
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
awu.html ./clinpharm/people/awu.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/awu.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
balldredge.html ./clinpharm/people/balldredge.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/balldredge.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
bconklin.html ./clinpharm/people/bconklin.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/bconklin.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Christine A. Haller, MD ./clinpharm/people/challer.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/challer.html</Path>
		<FileBody>
			
			&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/challer101.jpg&quot; align=right&gt;&lt;b&gt;Assistant Professor of Medicine, Clinical Pharmacology&lt;/b&gt;&lt;p&gt;
			
			&lt;b&gt;Research Interests&lt;/b&gt;&lt;br&gt;
			&lt;p style=&quot;margin&#45;left:11px&quot;&gt;Dr. Haller's current interests activities focus on the clinical safety of early drug development studies, particularly studies involving biologics and other novel therapeutics.  She is the chair of the Hepatotoxicity Advisory Committee and a member of the Safety Biomarkers Advisory Team at Amgen.  Dr. Haller is a member of the Critical Path Predictive Safety Testing Consortium Translational working group. Her previous work involved characterizing the pharmacology of herbal dietary supplements that contain ephedra, caffeine, and related stimulant botanicals.&lt;/p&gt;
			
			&lt;b&gt;Selected Publications&lt;/b&gt;&lt;p&gt;
			
			&lt;table border=0 style=&quot;margin&#45;left:11px&quot;&gt;
						&lt;TD&gt;
			&lt;b&gt;Haller CA&lt;/b&gt;, Kearney T, Bent S, Ko R, Benowitz NL, Olson K.  Dietary Supplement Adverse Events:  Report of a One&#45;Year Poison Center Surveillance Project.  J Med Tox 2008;4:84&#45;92.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			&lt;b&gt;Haller CA&lt;/b&gt;, Duan M, Jacob III P, Benowitz N.  Human Pharmacology of a Performance&#45;enhancing Dietary Supplement under Resting and Exercise Conditions.  Br J Clin Pharmacol 2008 65:833&#45;840.&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			&lt;b&gt;Haller C&lt;/b&gt;, Cosenza M, Sullivan JT. &quot;Safety Issues Specific to Clinical Development of Protein Therapeutics&quot; Clin Pharmacol and Therapeutics 2008;84(5):624&#45;627.&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/table&gt;&lt;br&gt;
			
			
			&lt;p&gt;&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
cpeck.html ./clinpharm/people/cpeck.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/cpeck.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
csmollin.html ./clinpharm/people/csmollin.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/csmollin.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Delia A. Dempsey, MD ./clinpharm/people/ddempsey.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/ddempsey.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; img src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/jschwartz75.jpg&quot; align=right &#45;&#45;&gt;&lt;b&gt;Assistant Professor, Pediatrics, Medicine, and Clinical Pharmacy&lt;/b&gt;&lt;p&gt;
			
			&lt;b&gt;Research Interests&lt;/b&gt;&lt;br&gt;
			&lt;p style=&quot;margin&#45;left:11px&quot;&gt;Dr. Dempsey's major research focus is on nicotine pharmacology and addiction in adults. She has studied nicotine metabolism and pharmacokinetics during pregnancy and in neonates. Currently she is also investigating pharmacokinetics and metabolism of biomarkers of second hand smoke exposure in young children and infants.  Dr. Dempsey also has a clinical interest in medical toxicology, adverse drug reactions (ADRs), medication errors and pediatric environmental health.&lt;/p&gt;
			
			&lt;b&gt;Selected Publications&lt;/b&gt;&lt;p&gt;
			
			&lt;table border=0 style=&quot;margin&#45;left:11px&quot;&gt;
						&lt;TD&gt;
			Tutka, P, &lt;b&gt;Dempsey, DA&lt;/b&gt;, Jacob, P, et al. (2008). Nicotine metabolism in pregnant and nonpregnant rabbits. &lt;i&gt;Nicotine and Tobacco Research&lt;/i&gt;, 10(8), 1385&#45;90.&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Levi, M, &lt;b&gt;Dempsey, DA&lt;/b&gt;, Benowitz, NL, et al. (2007). Population pharmacokinetics of nicotine and its metabolites I. Model development. &lt;i&gt;Journal of Pharmacokinetics and Pharmacodynamics&lt;/i&gt;, 34(1), 5&#45;21.&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Hukkanen, J, &lt;b&gt;Dempsey, D&lt;/b&gt;, Jacob, P, et al. (2005). Effect of pregnancy on a measure of FMO3 activity. &lt;i&gt;British Journal of Clinical Pharmacology&lt;/i&gt;, 60(2), 224&#45;6.&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/table&gt;&lt;br&gt;
			
			
			&lt;p&gt;&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
dkroetz.html ./clinpharm/people/dkroetz.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/dkroetz.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Dan Spyker, MD, PhD ./clinpharm/people/dspyker.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/dspyker.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; img src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/jschwartz75.jpg&quot; align=right &#45;&#45;&gt;&lt;b&gt;Adjunct Professor of Medicine and Bioengineering &amp; Therapeutic Sciences&lt;/b&gt;&lt;p&gt;
			
			&lt;b&gt;Research Interests&lt;/b&gt;&lt;br&gt;
			&lt;p style=&quot;margin&#45;left:11px&quot;&gt;Dr. Spyker served as a Medical Officer in the CDER's Pilot Drug Evaluation Staff from 1990 to 1993 when he joined CDRH as acting Deputy Director in the Division of Cardiovascular, Respiratory and Neurological Devices.  In 1999 he joined Purdue Pharma as Sr Medical Director and in 2004 joined Alexza Pharmaceuticals in Palo Alto as Sr Director of Drug Safety &amp; Pharmacovigilance.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:11px&quot;&gt;Dr. Spyker has been an active and enthusiastic participant in clinical pharmacology teaching of fellows at UCSF, with a particular emphasis on pharmacokinetic modeling design and reporting of clinical trials and in drug and medical device labeling.&lt;/p&gt;
			
			&lt;b&gt;Selected Publications&lt;/b&gt;&lt;p&gt;
			
			&lt;table border=0 style=&quot;margin&#45;left:11px&quot;&gt;
						&lt;TD&gt;
			Bronstein AC, &lt;b&gt;Spyker DA&lt;/b&gt;, Louis R. Cantilena LR, Green J, Rumack BH, Heard SE. 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol 2007; 45: 815&#45;917.&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Avram MJ, &lt;b&gt;Spyker DA&lt;/b&gt;, Henthorn TK, Cassella JV. The pharmacokinetics and bioavailability of prochlorperazine delivered as a thermally generated aerosol in a single breath to volunteers. Clin Pharmacol Ther 2008 (in press)&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/table&gt;&lt;br&gt;
			
			
			&lt;p&gt;&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
dverotta.html ./clinpharm/people/dverotta.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/dverotta.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
eburchard.html ./clinpharm/people/eburchard.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/eburchard.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
esmall.html ./clinpharm/people/esmall.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/esmall.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
eziv.html ./clinpharm/people/eziv.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/eziv.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Faculty Profiles ./clinpharm/people/faculty_profiles.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/faculty_profiles.html</Path>
		<FileBody>
			
		</FileBody>
	</node>
	<node>
		<Fname>
faweeka.html ./clinpharm/people/faweeka.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/faweeka.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Fellows ./clinpharm/people/fellows.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/fellows.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			
			
			
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/Doernberg2.jpg&quot;&gt;&lt;b&gt;Sarah Doernberg, MD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Sarah Doernberg is trained in Internal Medicine and is currently an Infectious Diseases fellow at UCSF. She is working with Drs &lt;a href=&quot;http://id.medicine.ucsf.edu/about/facpages/chambers.html&quot; target=&quot;_blank&quot;&gt;Chip Chambers&lt;/a&gt;, &lt;a href=&quot;http://www.faculty.uci.edu/profile.cfm?faculty_id=5274&quot; target=&quot;_blank&quot;&gt;Catherine Liu&lt;/a&gt;, and &lt;a href=&quot;http://id.medicine.ucsf.edu/about/facpages/winston.html&quot; target=&quot;_blank&quot;&gt;Lisa Winston&lt;/a&gt; and has a focus on hospital epidemiology and infection control. &lt;/p&gt;&lt;br clear=all&gt;&lt;br&gt;
			
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;
			&lt;br&gt;
			&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/chaass&#45;koffler101.jpg&quot; class=&quot;imgRight&quot;&gt;&lt;b&gt;Carolina Haass&#45;Koffler, PharmD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Carolina Haass&#45;Koffler completed her doctoral degree in Pharmacy in the Pharmaceutical Science Pathway and she is currently working with Drs &lt;a href=&quot;http://www.galloresearch.org/index.php/translationalresearch/preclinical/preclinicalmembers/23&#45;preclinicalmembers/83&#45;preclinicalselenab&quot; target=&quot;_blank&quot;&gt;Selena Bartlett&lt;/a&gt; and &lt;a href=&quot;http://www.galloresearch.org/index.php/investigators/abonci&quot; target=&quot;_blank&quot;&gt;Antonello Bonci&lt;/a&gt; in the Medication Development/Transitional Research group at the Ernest Gallo Clinic &amp; Research Center.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Haass&#45;Koffler's research interest is determining the physiological role of Corticotropin&#45;releasing&#45;factor binding&#45;protein (CRF&#45;BP), its interaction with its ligand (CRF) and receptors GPCRs. CRF&#45;BP was originally thought to have simply a buffer role, preventing excessive levels of CRF during stressful events. However, we postulate that CRF&#45;BP is not just a sink for CRF, but has an active role in the CRF&#45;mediate processes and the potentiation of NMDA receptor signaling. Dr. Haass&#45;Koffler is also interested in the effect of CRF&#45;BP on psychiatric disorders and its role in reinstatement of cocaine and alcohol seeking behaviors.&lt;/p&gt;
			
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;&lt;br&gt;
			
			
			
			
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/Kussmaul2.jpg&quot;&gt;&lt;b&gt;Susannah Kussmaul, MD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Susannah Kussmaul is a pediatrician who is interested in pharmacoepidemiology, specifically the judicious use of antibiotic therapy. She is working with Drs &lt;a href=&quot;http://clinicalpharmacy.ucsf.edu/faculty/bio.asp?bioid=%7BB1F14486&#45;3CB8&#45;48F8&#45;BEE0&#45;F4DFE718C5D1%7D&quot; target=&quot;_blank&quot;&gt;B. Joseph Guglielmo&lt;/a&gt; and &lt;a href=&quot;http://www.ucsfbenioffchildrens.org/cgi&#45;bin/expertDetail.cgi?doctorid=1287&quot; target=&quot;_blank&quot;&gt;Jay Tureen&lt;/a&gt; on a research project focusing on novel methods for treating intravascular&#45;related infections in children. She is concurrently completing a fellowship in Pediatric Infectious Diseases.&lt;/p&gt;&lt;br clear=all&gt;&lt;br&gt;
			&lt;br&gt;
			&lt;HR align=center width=&quot;60%&quot; color=#b33700 SIZE=1&gt;
			                  &lt;BR&gt;
			                  &lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/Munji.jpg&quot;&gt;&lt;b&gt;Roeben Munji, MD&lt;/b&gt;&lt;br&gt;
			                  &lt;P style=&quot;MARGIN&#45;LEFT: 12px&quot;&gt;Dr. Roeben Munji conducted his doctoral research in the field of neuroscience. He is currently working with Drs &lt;a href=&quot;http://profiles.ucsf.edu/ProfileDetails.aspx?Person=5506330&quot; target=&quot;_blank&quot;&gt;Roland Bainton&lt;/a&gt; and Richard Daneman on a research project focusing on identifying new genes and genetic pathways that regulate blood&#45;brain barrier (BBB) function. The BBB is a cellular and molecular barrier that protects the brain from injury and disease by inhibiting entry of pathogens, immune cells and xenobiotics, including therapeutic drugs, into the brain. His aims are to expand the understanding of BBB biology and identify targets for manipulating BBB permeability for the treatment of BBB&#45;associated neurological diseases and to enhance drug delivery to the brain.&lt;/P&gt;
			                  &lt;HR align=center width=&quot;60%&quot; color=#b33700 SIZE=1&gt;
			                  &lt;BR&gt; &lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles//Remsberg.jpg&quot; 
			                  align=right&gt;&lt;B&gt;Connie Remsberg, MD&lt;/B&gt;&lt;BR&gt;
			                  &lt;P style=&quot;MARGIN&#45;LEFT: 12px&quot;&gt;Dr. Connie Remsberg is a pharmacist that completed her Ph.D. in Pharmaceutical Sciences at Washington State University. She is currently working with &lt;a href=&quot;lbenet.html&quot;&gt;Dr. Leslie Benet&lt;/a&gt; on clinical studies involving pharmacokinetics, drug transporters, and drug&#45;drug interactions.&lt;/P&gt;
			
			&lt;br&gt;
			&lt;br&gt;
			&lt;br&gt;
			&lt;br&gt;
			&lt;br&gt;
			&lt;br&gt;
			&lt;b&gt;&lt;center&gt;PAST FELLOWS:&lt;/center&gt;&lt;/b&gt;&lt;br&gt;
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;&lt;br&gt;
			&lt;/br&gt;
			
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/afrymoyer101.jpg&quot;&gt;&lt;b&gt;Adam Frymoyer, MD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Adam Frymoyer is a pediatrician and worked with &lt;a href=&quot;lbenet.html&quot;&gt;Dr. Leslie Benet&lt;/a&gt;.   He studied drug transporters and participated in clinical studies of antibiotics in children.&lt;/p&gt;
			&lt;br clear=all&gt;&lt;br&gt;
			
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;&lt;br&gt;
			
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/jgalanter101.jpg&quot;&gt;&lt;b&gt;Joshua Galanter, MD&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Joshua Galanter is an internist with training in pulmonary and critical care medicine.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;He worked with &lt;a href=&quot;eburchard.html&quot;&gt;Dr. Esteban Burchard&lt;/a&gt;.  The focus of his research is the interplay between genetics, the environment and drug response, especially among children from minority populations.&lt;/p&gt;&lt;br clear=all&gt;&lt;br&gt;
			&lt;hr size=1 width=60% color=#B33700 align=center&gt;&lt;br&gt;
			
			&lt;img class=&quot;imgRight&quot; src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/wlorizio101.jpg&quot;&gt;&lt;b&gt;Wendy Lorizio, MD, MPH&lt;/b&gt;&lt;br&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Wendy Lorizio is trained in medicine and epidemiology and is working with Drs &lt;a href=&quot;eziv.html&quot;&gt;Elad Ziv&lt;/a&gt; and &lt;a href=&quot;eburchard.html&quot;&gt;Esteban Burchard&lt;/a&gt;.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:12px&quot;&gt;Dr. Lorizio's research interests are cancer, genetic epidemiology and pharmacogenetics, with a particular focus on minority populations, especially Latinas. Her specific research project will be to study the interaction among genetic polymorphisms of the estrogen receptor alpha and beta genes, the &lt;i&gt;CYP2D6&lt;/i&gt; gene and serum biomarkers such as IGF&#45;1 and osteocalcin as predictors of adverse effects from tamoxifen in women being treated for breast cancer. Dr Lorizio is also planning to study the decision process of women deciding whether to take tamoxifen and how &lt;i&gt;CYP2D6&lt;/i&gt; genotyping affects that decision.&lt;/p&gt;&lt;br clear=all&gt;&lt;br&gt;
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
hchambers.html ./clinpharm/people/hchambers.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/hchambers.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Howard K. Lee, MD, PhD ./clinpharm/people/hlee.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/hlee.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; img src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/jschwartz75.jpg&quot; align=right &#45;&#45;&gt;&lt;b&gt;Associate Adjunct Professor, Bioengineering &amp; Therapeutic Sciences&lt;/b&gt;&lt;p&gt;
			
			&lt;b&gt;Research Interests&lt;/b&gt;&lt;br&gt;
			&lt;p style=&quot;margin&#45;left:11px&quot;&gt;Howard Lee, MD, PhD, is based at the Center for Drug Development Science at the UCSF campus in Washington D.C.  His academic interest is in the area of drug development science.  Dr. Lee has developed innovative population pharmacokinetic&#45;pharmacodynamic models for blood pressure responses to antihypertensive drugs and for the effects of etanercept in trials of treatment of rheumatoid arthritis.  Dr. Lee has worked closely with the FDA and has mentored fellows in the area of drug development.&lt;/p&gt;
			
			&lt;b&gt;Selected Publications&lt;/b&gt;&lt;p&gt;
			
			&lt;table border=0 style=&quot;margin&#45;left:11px&quot;&gt;
						&lt;TD&gt;
			Rea RS, Capitano B, Bies R, Bigos KL, Smith R, &lt;b&gt;Lee H&lt;/b&gt;. Suboptimal Aminoglycoside Dosing in Critically Ill Patients, Therapeutic Drug Monitoring, 2008 (accepted for publication)&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			O'brien S, &lt;b&gt;Lee H&lt;/b&gt;, Ritchey, AK. Once&#45;Daily Enoxaparin in Pediatric Thromboembolism: A Dose Finding and Pharmacodynamics Study, Journal of Thrombosis and Haemostasis, May 21, 2007&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, &lt;b&gt;Lee H&lt;/b&gt;. Population Pharmacokinetic Analysis and Simulation of the Time Concentration Profile of Etanercept in Pediatric Patients with Juvenile Rheumatoid Arthritis, &lt;i&gt;Journal of Clinical Pharmacology&lt;/i&gt;, 2005;45(3):246&#45;256
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/table&gt;&lt;br&gt;
			
			
			&lt;p&gt;&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
People ./clinpharm/people/index-old.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/index-old.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Faculty ./clinpharm/people/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/index.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			Faculty members responsible for the teaching and fellowship training activities of the Division include:&lt;p&gt;
			
			&lt;table border=0 style=&quot;margin&#45;left:11px&quot;cellpadding=3&gt;
			&lt;TR valign=top&gt;
			&lt;td width=50%&gt;
			
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;nahituv.html&quot;&gt;Nadav Ahituv, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;balldredge.html&quot;&gt;Brian Alldredge, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;faweeka.html&quot;&gt;Francesca Aweeka, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;lbenet.html&quot;&gt;Leslie Z. Benet, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;nbenowitz.html&quot;&gt;Neal L. Benowitz, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;eburchard.html&quot;&gt;Esteban Gonz&amp;aacute;lez Burchard, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;mcabana.html&quot;&gt;Michael Cabana, MD, MPH&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;hchambers.html&quot;&gt;Henry F. Chambers, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;mcorreia.html&quot;&gt;Maria Almira Correia, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;lfloren.html&quot;&gt;Leslie Floren, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/joshua.galanter&quot;&gt;Josh Galanter, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;kgiacomini.html&quot;&gt;Kathleen M. Giacomini, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;jguglielmo.html&quot;&gt;B. Joseph Guglielmo, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;mheyman.html&quot;&gt;Melvin Heyman, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;pjacob.html&quot;&gt;Peyton Jacob, III, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;rkrauss.html&quot;&gt;Ronald Krauss, MD&lt;/a&gt;
			&lt;/ul&gt;
			&lt;/td&gt;&lt;td&gt;
			&lt;ul&gt;
			
			&lt;li&gt;&lt;a href=&quot;dkroetz.html&quot;&gt;Deanna L. Kroetz, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/janel.long&#45;boyle&quot;&gt;Janel Long&#45;Boyle, PhD, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;pmunster.html&quot;&gt;Pamela Munster, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;kolson.html&quot;&gt;Kent R. Olson, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;cpeck.html&quot;&gt;Carl C. Peck, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;kphillips.html&quot;&gt;Kathryn Phillips, PhD, MPA&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;jpuck.html&quot;&gt;Jennifer Puck, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;nsambol.html&quot;&gt;Nancy C. Sambol, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/rada.savic&quot;&gt;Rada Savic, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;jschwartz.html&quot;&gt;Janice B. Schwartz, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/jaekyu.shin&quot;&gt;Jaekyu Shin, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;esmall.html&quot;&gt;Eric Small, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://pediatrics.medschool.ucsf.edu/genpeds/faculty/bios/thyne_s.aspx&quot;&gt;Shannon Thyne, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;dverotta.html&quot;&gt;Davide Verotta, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://profiles.ucsf.edu/alan.wu&quot;&gt;Alan Wu, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;eziv.html&quot;&gt;Elad Ziv, MD&lt;/a&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/table&gt;
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Faculty ./clinpharm/people/index.html~
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/index.html~</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			Faculty members responsible for the teaching and fellowship training activities of the Division include:&lt;p&gt;
			
			&lt;table border=0 style=&quot;margin&#45;left:11px&quot;cellpadding=3&gt;
			&lt;TR valign=top&gt;
			&lt;td width=50%&gt;
			
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;nahituv.html&quot;&gt;Nadav Ahituv, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;balldredge.html&quot;&gt;Brian Alldredge, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;faweeka.html&quot;&gt;Francesca Aweeka, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;lbenet.html&quot;&gt;Leslie Z. Benet, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;nbenowitz.html&quot;&gt;Neal L. Benowitz, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;eburchard.html&quot;&gt;Esteban Gonz&amp;aacute;lez Burchard, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;mcabana.html&quot;&gt;Michael Cabana, MD, MPH&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;hchambers.html&quot;&gt;Henry F. Chambers, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;mcorreia.html&quot;&gt;Maria Almira Correia, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;lfloren.html&quot;&gt;Leslie Floren, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;kgiacomini.html&quot;&gt;Kathleen M. Giacomini, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;jguglielmo.html&quot;&gt;B. Joseph Guglielmo, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;mheyman.html&quot;&gt;Melvin Heyman, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;pjacob.html&quot;&gt;Peyton Jacob, III, PhD&lt;/a&gt;
			&lt;/ul&gt;
			&lt;/td&gt;&lt;td&gt;
			&lt;ul&gt;
			
			&lt;li&gt;&lt;a href=&quot;rkrauss.html&quot;&gt;Ronald Krauss, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;dkroetz.html&quot;&gt;Deanna L. Kroetz, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;pmunster.html&quot;&gt;Pamela Munster, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;kolson.html&quot;&gt;Kent R. Olson, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;cpeck.html&quot;&gt;Carl C. Peck, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;kphillips.html&quot;&gt;Kathryn Phillips, PhD, MPA&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;jpuck.html&quot;&gt;Jennifer Puck, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;nsambol.html&quot;&gt;Nancy C. Sambol, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;jschwartz.html&quot;&gt;Janice B. Schwartz, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;esmall.html&quot;&gt;Eric Small, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;http://pediatrics.medschool.ucsf.edu/genpeds/faculty/bios/thyne_s.aspx&quot;&gt;Shannon Thyne, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;dverotta.html&quot;&gt;Davide Verotta, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;eziv.html&quot;&gt;Elad Ziv, MD&lt;/a&gt;
			&lt;/ul&gt;
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/table&gt;
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
jguglielmo.html ./clinpharm/people/jguglielmo.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/jguglielmo.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
jkarliner.html ./clinpharm/people/jkarliner.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/jkarliner.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
jpuck.html ./clinpharm/people/jpuck.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/jpuck.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Janice B. Schwartz, MD ./clinpharm/people/jschwartz.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/jschwartz.html</Path>
		<FileBody>
			
			&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/jschwartz101.jpg&quot; align=right&gt;&lt;b&gt;Clinical Professor of Medicine&lt;/b&gt;&lt;p&gt;
			
			&lt;b&gt;Research Interests&lt;/b&gt;&lt;br&gt;
			&lt;p style=&quot;margin&#45;left:11px&quot;&gt;Janice B. Schwartz, M.D., was recruited in September 2001 as director of Research at the Jewish Home. In 2004, the Jewish Home's research activities became independent under the direction of the Research department. A major focus of her research is to study how consumption of multiple medications puts the older patient at increased risk for drug interactions and hospitalizations due to drug&#45;related problems. By developing &quot;potentially optimized prescribing (POP)&quot; algorithms, it is predicted that fewer medications will be prescribed, there will be fewer unwanted effects, and the treatment will be appropriate and effective for the older patient. Additionally, her research group is investigating how age, gender, or ethnicity can affect the removal of medications from the body.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:11px;&quot;&gt;Dr. Schwartz's research encompass traditional pharmacokinetic studies, population pharmacokinetic studies of understudied groups such as the frail elderly, and pharmacodynamic studies. The focus is on clinical research studies mechanistic studies in humans. Inpatient studies are usually performed in the clinical translational research institute clinical research center and outpatient studies at a number of community sites. Animal and tissue models of aging are used when appropriate.&lt;/p&gt;
			
			&lt;p style=&quot;margin&#45;left:11px&quot;&gt;Additional opportunities include scholarly reviews of pharmacologic therapies that are gender specific, development of educational methods for optimizing prescribing for patients, and clinical therapeutic trials.&lt;/p&gt;
			
			&lt;b&gt;Selected Publications&lt;/b&gt;&lt;p&gt;
			
			&lt;table border=0 style=&quot;margin&#45;left:11px&quot;&gt;
						&lt;TD&gt;
			Kang D, Verotta D, &lt;b&gt;Schwartz JB&lt;/b&gt;.  Population analyses of amlodipine in patients living in the community and nursing homes.  Clin Pharmacol Ther, 2006;79:114&#45;124.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			&lt;b&gt;Schwartz, JB&lt;/b&gt;.  Erythromycin clearance in the elderly, very elderly, and frail elderly. Clin Pharmacol Ther, 2006;79:440&#45;88.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			&lt;b&gt;Schwartz, JB&lt;/b&gt;.   Effects of vitamin D supplementation on cholesterol and atorvastatin concentrations in atorvastatin treated patients. Clin Pharmacol Ther, advance online publication 27 August 2008. doi:10.1038/clpt.2008.165.
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/table&gt;&lt;br&gt;
			
			
			&lt;p&gt;&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
kgiacomini.html ./clinpharm/people/kgiacomini.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/kgiacomini.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Kent R. Olson, MD, FACEP, FAACT, FACMT ./clinpharm/people/kolson.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/kolson.html</Path>
		<FileBody>
			
			&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/kolson75.jpg&quot; align=right&gt;&lt;b&gt;Clinical Professor of Medicine, Pediatrics and Pharmacy, UC San Francisco&lt;br&gt;
			Clinical Professor of Health &amp; Medical Sciences, UC Berkeley&lt;/b&gt;&lt;p&gt;
			
			Poison Control Center&lt;br&gt;
			UC San Francisco Box 1369&lt;br&gt;
			San Francisco, CA 94143&#45;1369&lt;br&gt;
			&lt;a href=&quot;mailto:olson@calpoison.org&quot;&gt;olson@calpoison.org&lt;/a&gt;&lt;br&gt;
			415&#45;502&#45;6002&lt;p&gt;
			
			Kent R. Olson, MD is the Medical Director of the San Francisco Division of the California Poison Control System. He completed a bachelor's degree in Chemistry at Boston University and his medical degree at UC San Francisco. He is board&#45;certified in emergency medicine and medical toxicology. He is the Editor of &lt;i&gt;Poisoning &amp; Drug Overdose&lt;/i&gt; (McGraw&#45;Hill, 2007), now in its 5&lt;sup&gt;th&lt;/sup&gt; edition.&lt;p&gt;
			
			&lt;b&gt;Research Interests&lt;/b&gt;&lt;br&gt;
			&lt;p style=&quot;margin&#45;left:11px&quot;&gt;His research interests include the diagnosis and management of acute poisoning, and cost&#45;effectiveness of poison control centers. He is also very committed to preclinical medical education and is on the core faculty of the UC Berkeley&#45;UCSF Joint Medical Program at UC Berkeley, where he serves as the content expert in pharmacology and a small&#45;group tutor and unit steward for its Contextually&#45;Integrated Case&#45;Based Curriculum.&lt;/p&gt;
			
			&lt;b&gt;Selected Publications&lt;/b&gt;&lt;p&gt;
			
			&lt;table border=0 style=&quot;margin&#45;left:11px&quot;&gt;
						&lt;TD&gt;
			Calcium channel blocker ingestion: an evidence&#45;based consensus guideline for out&#45;of&#45;hospital management. &lt;b&gt;Olson KR&lt;/b&gt;, Erdman AR, Woolf AD, Scharman EJ, Christianson C, Caravati EM, Wax PM, Booze LL, Manoguerra AS, Keyes DC, Chyka PA, Troutman WG. Clin Toxicol (Phila). 2005;43:797&#45;821.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Hyperbaric Oxygen or Normobaric Oxygen? (Editorial). &lt;b&gt;Olson KR&lt;/b&gt;. Toxicology Reviews 2005; 24(3):1.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Protocols for pediatric poisonings from nontoxic substances: are they valid? Kearney TE, Van Bebber SL, Hiatt PH, &lt;b&gt;Olson KR&lt;/b&gt;. Pediatr Emerg Care. 2006 Apr;22(4):215&#45;21.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Evolving epidemiology of drug&#45;induced seizures reported to a poison control center system. Thundiyil JG, Kearney TE, &lt;b&gt;Olson KR&lt;/b&gt;. J Med Toxicol 2007; 3(1):15&#45;19.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Patterns of Ecstasy&#45;Associated Hyponatremia in California. Rosenson J, Smollin C, Sporer KA, Blanc P, &lt;b&gt;Olson KR&lt;/b&gt;.  Ann Emerg Med 2007; 49(2):164&#45;71.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Alternative Models for Telephone Response to Pediatric Poisonings. Kearney TE, Hiatt PH, &lt;b&gt;Olson KR&lt;/b&gt;. Prehosp Emerg Care 2007; 11(3):284&#45;92.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Case files of the medical toxicology fellowship of the California Poison Control System&#45;San Francisco: Calcium plus digoxin&#45;more taboo than toxic? Erickson CP, &lt;b&gt;Olson KR&lt;/b&gt;: J Medical Toxicol 2008; 4:33&#45;9.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Dietary supplement adverse events: report of a one&#45;year poison center surveillance project. Haller C, Kearney T, Bent S, Ko R, Benowitz N, &lt;b&gt;Olson K&lt;/b&gt;. J Med Toxicol. 2008 Jun;4(2):84&#45;92.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Acute quetiapine overdose in adults: a 5&#45;year retrospective case series. Ngo AS, Ciranni M, &lt;b&gt;Olson KR&lt;/b&gt;: Ann Emerg Med 2008; 52:541&#45;7.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			The clinical utility of a seizure panel to detect common drugs involved in drug&#45;induced seizures using LC&#45;MS/MS. Drees JC, Stone JA, &lt;b&gt;Olson KR&lt;/b&gt;, Meier KH, Gelb AM, Wu AHB: Clinical Chem 2009; 55(1):126&#45;33.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Comparing the acute toxicity of first&#45;generation vs. second&#45;generation antipsychotic drugs: a 10&#45;year retrospective cohort study. Ciranni M, Ngo A, &lt;b&gt;Olson KR&lt;/b&gt;: J Clin Psychiatry 2009; 70:122&#45;9.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Dart RC, Borron SW, Caravati EM, Cobaugh DJ, Curry SC, Falk JL, Goldfrank L, Gorman SE, Groft S, Heard K, Miller K, &lt;b&gt;Olson KR&lt;/b&gt;, O'Malley G, Seger D, Seifert SA, Sivilotti MLA, Schaeffer T, Tomassoni AJ, Wise R, Bogdan GM, Alhelail M, Buchanan J, Hoppe J, Lavonas E, Mylnarcheck D, Phua D&#45;H, Rhyee S, Varney S, Zosel A. Ann Emerg Med 2009.
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/table&gt;&lt;br&gt;
			
			
			&lt;p&gt;&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
kphillips.html ./clinpharm/people/kphillips.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/kphillips.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
lbenet.html ./clinpharm/people/lbenet.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/lbenet.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
lbero.html ./clinpharm/people/lbero.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/lbero.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Leslie Carstensen Floren, PharmD ./clinpharm/people/lfloren.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/lfloren.html</Path>
		<FileBody>
			
			&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/lfloren75.jpg&quot; align=right&gt;&lt;b&gt;Assistant Adjunct Professor of Bioengineering &amp; Therapeutic Sciences&lt;/b&gt;&lt;p&gt;
			
			&lt;b&gt;Research Interests&lt;/b&gt;&lt;br&gt;
			&lt;p style=&quot;margin&#45;left:11px&quot;&gt;Dr. Floren is one of the core teaching faculty in the Clinical Pharmacology Training Program, serving as the faculty mentor for most of the Principles in Clinical Pharmacology seminars.  She also provides an intensive series of workshops each summer for the Fellows based upon the UCSF Pharmacokinetics for Pharmaceutical Scientists course, of which she is also a faculty member. Dr. Floren is also involved with the UCSF&#45;sponsored American Course on Drug Development and Regulatory Sciences and is developing a Pharmacokinetic/Pharmacodynamic/Pharmacogenomic Core to support the UCSF Comprehensive Cancer Center's Early Phase Clinical Trials Program.&lt;/p&gt;
			
			&lt;!&#45;&#45; b&gt;Selected Publications&lt;/b&gt;&lt;p&gt;
			
			&lt;table border=0 style=&quot;margin&#45;left:11px&quot;&gt;
						&lt;TD&gt;
			Bronstein AC, &lt;b&gt;Spyker DA&lt;/b&gt;, Louis R. Cantilena LR, Green J, Rumack BH, Heard SE. 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol 2007; 45: 815&#45;917.&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Avram MJ, &lt;b&gt;Spyker DA&lt;/b&gt;, Henthorn TK, Cassella JV. The pharmacokinetics and bioavailability of prochlorperazine delivered as a thermally generated aerosol in a single breath to volunteers. Clin Pharmacol Ther 2008 (in press)&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/table&gt;&lt;br &#45;&#45;&gt;
			
			
			&lt;p&gt;&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
mcabana.html ./clinpharm/people/mcabana.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/mcabana.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
mcorreia.html ./clinpharm/people/mcorreia.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/mcorreia.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
mgray.html ./clinpharm/people/mgray.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/mgray.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
mheyman.html ./clinpharm/people/mheyman.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/mheyman.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
nahituv.html ./clinpharm/people/nahituv.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/nahituv.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
nbenowitz.html ./clinpharm/people/nbenowitz.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/nbenowitz.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Nancy C. Sambol, PharmD ./clinpharm/people/nsambol.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/nsambol.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; img src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/jschwartz75.jpg&quot; align=right &#45;&#45;&gt;&lt;b&gt;Associate Professor Bioengineering &amp; Therapeutic Sciences and Clinical Pharmacy&lt;/b&gt;&lt;p&gt;
			
			&lt;b&gt;Research Interests&lt;/b&gt;&lt;br&gt;
			&lt;p style=&quot;margin&#45;left:11px&quot;&gt;The primary goal of Dr. Sambol's research group is to advance methods of new drug development as they relate to pharmacokinetics (PK) and pharmacodynamics (PD), particularly population approaches (those that consider patient traits and variability).  Pharmaceutical companies and other investigators provide real&#45;life issues and challenges on which their work is based.  Ongoing and future investigations include the following issues:  1) population PK/PD study design and analysis when data are censored (e.g., analgesic trials and bronchoprovocation studies); 2) population PK/PD study design and analysis for investigating genetic variables, particularly with respect to cancer chemotherapeutic agents; and 3) utilization of population PK models for individualizing cancer chemotherapy administration.&lt;/p&gt;
			
			&lt;b&gt;Selected Publications&lt;/b&gt;&lt;p&gt;
			
			&lt;table border=0 style=&quot;margin&#45;left:11px&quot;&gt;
						&lt;TD&gt;
			Liu CY, &lt;b&gt;Sambol NC&lt;/b&gt;. Nonlinear mixed effects models of analgesic trial data. J Biopharm Stat, 9(2):253&#45;270, 1999.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			&lt;b&gt;Sambol NC&lt;/b&gt;, Liu CY, Williams P, Baker J. Population method is critical to dose&#45;response assessment of a bronchodilator studied with a bronchoprovocation design. &lt;i&gt;In European Cooperation in the Field of Scientific and Technical Research: The Population Approach: Measuring and Managing Variability in Response, Concentration and Dose&lt;/i&gt;, pp. 337&#45;341. Edited by Aarons L, Balant LP, Danhof M, Gex&#45;Fabry M, Gundert&#45;Remy UA, Karlsson MO, Mentre F, Morselli PL, Rombout F, Rowland M, Steimer LL and Vozeh S. Brussels, Luxembourg, 1997. 
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			&lt;b&gt;Sambol NC&lt;/b&gt;, Chiang J, O'Conner M, Liu CY, Lin ET, Goodman AM, Benet LZ, Karam JH. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin&#45;dependent diabetes mellitus. &lt;i&gt;J Clin Pharmacol&lt;/i&gt;, 36(11):1012&#45;1021, 1996. &lt;/td&gt;
			&lt;/tr&gt;
			&lt;/table&gt;&lt;br&gt;
			
			
			&lt;p&gt;&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
pblanc.html ./clinpharm/people/pblanc.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/pblanc.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
pjacob.html ./clinpharm/people/pjacob.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/pjacob.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
pmunster.html ./clinpharm/people/pmunster.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/pmunster.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
rjones.html ./clinpharm/people/rjones.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/rjones.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Ronald M. Krauss, MD ./clinpharm/people/rkrauss.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/rkrauss.html</Path>
		<FileBody>
			
			&lt;img src=&quot;/sites/clinpharm.ucsf.edu/files/images/profiles/rkrauss101.jpg&quot; align=right&gt;&lt;b&gt;Senior Scientist, Children's Hospital Research Institute&lt;br&gt;
			Associate Adjunct Professor of Medicine&lt;/b&gt;&lt;p&gt;
			
			&lt;b&gt;Research Interests&lt;/b&gt;&lt;br&gt;
			&lt;p style=&quot;margin&#45;left:11px&quot;&gt;Dr. Krauss' research program focuses on plasma lipoprotein metabolism and related traits that influence risk for coronary artery disease. His laboratory developed and applied methodology that led to the discovery of a common genetically&#45;influenced atherogenic lipoprotein phenotype that underlies cardiovascular disease risk in patients with obesity, type 2 diabetes, and metabolic syndrome.  A major current research emphasis has been the identification of genetic determinants of the wide range of inter&#45;individual variability in phenotypic and clinical response to statin treatment. Multiple statin&#45;treated population samples are being examined to test the reproducibility and generalizability of findings derived from both candidate gene and genome&#45;wide searches for SNP associations with markers of statin efficacy as well as muscle toxicity. Functional significance of genetic findings is being evaluated in appropriate human cellular and animal models, with the goal of connecting genotypes to clinically relevant determinants of cardiovascular disease risk.&lt;/p&gt;
			
			&lt;b&gt;Selected Publications&lt;/b&gt;&lt;p&gt;
			
			&lt;table border=0 style=&quot;margin&#45;left:11px&quot;&gt;
						&lt;TD&gt;
			Simon, J.A., F. Lin, S.B. Hulley, P.J. Blanche, D. Waters, S. Shiboski, J.I. Rotter, D.A. Nickerson, H. Yang, M. Saad and &lt;b&gt;R.M. Krauss&lt;/b&gt;.  Phenotypic predictors of response to simvastatin therapy among African Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. &lt;i&gt;Am J Cardiology&lt;/i&gt;. 97:843&#45;850, 2006. &lt;/tr&gt;
						&lt;TD&gt;
			&lt;b&gt;Krauss, R.M.&lt;/b&gt;, L.M. Mangravite, J.D. Smith, M.W. Medina, D. Wang, X. Guo, M.J. Rieder, J.A. Simon, S.B. Hulley, D. Waters, M. Saad, P.T. Williams, K.D. Taylor, H. Yang, D.A. Nickerson, and J.I. Rotter. Variation in the Hydroxymethyl Glutaryl Coenzyme A Reductase Gene Is Associated With Racial Differences in Low&#45;Density Lipoprotein Cholesterol Response to Simvastatin Treatment. &lt;i&gt;Circulation&lt;/i&gt;. 117:1537&#45;44, 2008.
			&lt;/td&gt;
			&lt;/tr&gt;
						&lt;TD&gt;
			Medina, M.W., F. Gao, W. Ruan, J.I. Rotter and &lt;b&gt;R.M. Krauss&lt;/b&gt;. Alternative splicing of &lt;i&gt;HMGCR&lt;/i&gt; is associated with plasma LDL cholesterol response to simvastatin. &lt;i&gt;Circulation&lt;/i&gt;,118:355&#45;362, 2008.
			&lt;/td&gt;
			&lt;/tr&gt;
			&lt;/table&gt;
			
			
			&lt;p&gt;&lt;br&gt;
			
					</FileBody>
	</node>
	<node>
		<Fname>
tkearney.html ./clinpharm/people/tkearney.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/people/tkearney.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
index.html ./clinpharm/res/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/res/index.html</Path>
		<FileBody>
		</FileBody>
	</node>
	<node>
		<Fname>
Research ./clinpharm/research/index.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/research/index.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			
			&lt;p class=&quot;bluify&quot;&gt;The fellowship research experience is the heart of the training program. Each of the investigators listed below conducts an active, independently funded research program directed at clinical and/or basic problems in therapeutics or toxicology. From this group each fellow chooses a mentor who will supervise the fellow's research during the fellowship period.&lt;/p&gt;
			
			To provide prospective applicants with some knowledge of the breadth and depth of the research opportunities available, the interests of potential mentors and research groups are described below, along with representative publications.&lt;p&gt;
			
			&lt;table border=0 cellspacing=6px style=&quot;margin:12px;&quot;&gt;
			&lt;tr valign=top&gt;&lt;td width=50%&gt;&lt;b&gt;Cardiovascular Pharmacology&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/people/mgray.html&quot;&gt;Mary O. Gray, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/jkarliner.html&quot;&gt;Joel S. Karliner, MD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Drug Development &amp; Regulatory Science&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/people/hlee.html&quot;&gt;Howard K. Lee, MD, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/cpeck.html&quot;&gt;Carl C. Peck, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/dspyker.html&quot;&gt;Daniel A. Spyker, MD, PhD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Geriatric Clinical Pharmacology&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/people/jschwartz.html&quot;&gt;Janice B. Schwartz, MD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Health Policy Studies&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/people/lbero.html&quot;&gt;Lisa Bero, PhD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Infectious Diseases &amp; Antimicrobial Research&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/people/hchambers.html&quot;&gt;Henry F. Chambers, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/jguglielmo.html&quot;&gt;B. Joseph Guglielmo, PharmD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Investigational Therapeutics&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/people/pmunster.html&quot;&gt;Pamela N. Munster, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/esmall.html&quot;&gt;Eric Small, MD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Medical Toxicology&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/people/challer.html&quot;&gt;Christine Haller, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/kolson.html&quot;&gt;Kent R. Olson, MD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;/td&gt;&lt;td width=50%&gt;
			&lt;b&gt;Neuropsychopharmacology &amp; Analgesiology&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/people/balldredge.html&quot;&gt;Brian K. Alldredge, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/rjones.html&quot;&gt;Reese T. Jones, MD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Pediatric Clinical Pharmacology&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/people/mcabana.html&quot;&gt;Michael Cabana, MD, MPH&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/mheyman.html&quot;&gt;Melvin B. Heyman, MD, MPH&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/rkrauss.html&quot;&gt;Ronald M. Krauss, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/jpuck.html&quot;&gt;Jennifer M. Puck, MD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Personalized Medicine&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/people/kphillips.html&quot;&gt;Kathryn A. Phillips, PhD, MPA&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Pharmacogenetics, Molecular Pharmacology, Pharmacodynamics &amp; Drug Disposition&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/people/nahituv.html&quot;&gt;Nadav Ahituv, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/faweeka.html&quot;&gt;Francesca T. Aweeka, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/lbenet.html&quot;&gt;Leslie Z. Benet, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/nbenowitz.html&quot;&gt;Neal L. Benowitz, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/eburchard.html&quot;&gt;Esteban Gonz&amp;aacute;lez Burchard, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/bconklin.html&quot;&gt;Bruce Conklin, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/mcorreia.html&quot;&gt;Maria Almira Correia, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/ddempsey.html&quot;&gt;Delia A. Dempsey, MD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/lfloren.html&quot;&gt;Leslie Carstensen Floren, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/kgiacomini.html&quot;&gt;Kathleen M. Giacomini, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/pjacob.html&quot;&gt;Peyton Jacob III, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/dkroetz.html&quot;&gt;Deanna L. Kroetz, PhD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/eziv.html&quot;&gt;Elad Ziv, MD&lt;/a&gt;
			&lt;/ul&gt;
			
			&lt;b&gt;Pharmacometrics&lt;/b&gt;&lt;br&gt;
			&lt;ul&gt;
			&lt;li&gt;&lt;a href=&quot;/people/nsambol.html&quot;&gt;Nancy C. Sambol, PharmD&lt;/a&gt;
			&lt;li&gt;&lt;a href=&quot;/people/dverotta.html&quot;&gt;Davide Verotta, PhD&lt;/a&gt;
			&lt;/ul&gt;
			&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
	<node>
		<Fname>
Clinical Pharmacology Lab ./clinpharm/research/lab.html
		</Fname>
		<Tax>1736</Tax>
		<Path>./clinpharm/research/lab.html</Path>
		<FileBody>
			
			&lt;!&#45;&#45; #BeginEditable &quot;Content&quot; &#45;&#45;&gt;
			The Clinical Pharmacology Laboratory at SFGH is under the leadership of &lt;a href=&quot;/people/nbenowitz.html&quot;&gt;Dr. Neal Benowitz, MD&lt;/a&gt;, an expert on smoking and health, and in particular the human pharmacology of nicotine. The division conducts research projects that focus on the study of human pharmacology of nicotine, with an emphasis on nicotine addiction. Among the issues currently being explored and studied include (1) the role of nicotine in controlling cigarette smoking and the use of other forms of tobacco; (2) the pathways and genetics of nicotine metabolism and pharmacological activity of nicotine breakdown substances; (3) phamacogenetics of nicotine addiction treatment; (4) racial/ethnic differences in nicotine pharmacology and addiction; (5) assessment of exposure to tobacco smoke in smokers and people exposed to secondhand smoke; &lt;a href=&quot;http://www.famri.org/core/&quot; target=&quot;_blank&quot;&gt;http://www.famri.org/core/&lt;/a&gt; (6) nicotine based tobacco regulation interventions; and (7) studies of exposure to smoke constituents from Hookah smoking and other novel smoking products.&lt;p&gt;
			
			Many of the Division's research projects involve measuring biofluid concentrations of drugs and metabolites, and biomarkers for toxic substance exposure.  The Clinical Pharmacology Laboratory (CPL), located at San Francisco General Hospital Medical Center, provides analytical chemistry support for research projects in the Division. In addition, CPL performs analyses to measure nicotine and/or its metabolites, caffeine and/or its metabolites, minor tobacco alkaloids, smoking cessation medications and selected carcinogen biomarkers for investigators outside our unit on a recharge or fee for service basis.&lt;p&gt;
			
			The CPL is directed by &lt;a href=&quot;/people/pjacob.html&quot;&gt;Dr. Peyton Jacob, III, PhD&lt;/a&gt;, and staffed with a team of 10 research personnel. The Laboratory is equipped with three triple&#45;quadrupole mass spectrometers (both GC and LC interfaces), a desktop GC&#45;MS system, HPLCs and GCs.  The CPL typically analyzes 10,000&#45;15,000 samples annually.&lt;p&gt;
			
			The Laboratory has been designated as a Core (Tobacco Biomarkers) for the UCSF Helen Diller Family Comprehensive Cancer Center. For more information about our Core facility, including a description of the analytical methods carried out at the CPL, their applications, and fee schedule, visit &lt;a href=&quot;http://cancer.ucsf.edu/tobacco&#45;biomarkers/&quot; target=&quot;_blank&quot;&gt;our website&lt;/a&gt;.&lt;p&gt;
			
			&lt;!&#45;&#45; #EndEditable &#45;&#45;&gt;
			
			
					</FileBody>
	</node>
</nodes>